| Year |
Citation |
Score |
| 2024 |
Strauss JD, Gilbert MR, Mehta M, Li A, Ms RZ, Bondy ML, Sulman EP, Yuan Y, Liu Y, Vera E, Wendland MM, Stieber VW, Puduvalli VK, Choi S, Martinez NL, et al. Clinical and Genetic Markers of Vascular Toxicity in Glioblastoma Patients: Insights from NRG Oncology RTOG-0825. Neuro-Oncology. PMID 39549280 DOI: 10.1093/neuonc/noae234 |
0.487 |
|
| 2024 |
Pascoe M, Byrne E, King A, Cooper D, Foldvary-Schaefer N, Mehra R, Lathia J, Gilbert MR, Armstrong TS. Sleep disorders associated with cranial radiation - a systematic review. Neuro-Oncology. PMID 39468721 DOI: 10.1093/neuonc/noae174 |
0.465 |
|
| 2024 |
Kim Y, Armstrong TS, Gilbert MR, Celiku O. Disparities in the availability and access to Neuro-Oncology Trial-Supporting infrastructure in the United States. Journal of the National Cancer Institute. PMID 39325856 DOI: 10.1093/jnci/djae240 |
0.441 |
|
| 2024 |
Pascoe MM, Wollet AR, De La Cruz Minyety J, Vera E, Miller H, Celiku O, Leeper H, Fernandez K, Reyes J, Young D, Acquaye-Mallory A, Adegbesan K, Boris L, Burton E, Chambers CP, ... ... Gilbert MR, et al. Assessing sleep in primary brain tumor patients using smart wearables and patient-reported data: Feasibility and interim analysis of an observational study. Neuro-Oncology Practice. 11: 640-651. PMID 39279778 DOI: 10.1093/nop/npae048 |
0.505 |
|
| 2024 |
Obrecht-Sturm D, Schoof M, Eckhardt A, Mynarek M, Gilbert MR, Aldape K, Armstrong TS, Ramaswamy V, Bockmayr M, von Hoff K, Fleischhack G, Adolph JE, Tippelt S, Pfister SM, Pajtler K, et al. Distinct relapse pattern across molecular ependymoma types. Neuro-Oncology. PMID 39171767 DOI: 10.1093/neuonc/noae166 |
0.395 |
|
| 2024 |
Acquaye-Mallory A, Vera E, Choi A, Wall K, Gilbert MR, Armstrong TS. Identifying associations between sample characteristics, symptoms, and self-efficacy differences in adult patients with rare tumors of the central nervous system who participated in a novel web-based natural history study. Cancer Medicine. 13: e70017. PMID 39101481 DOI: 10.1002/cam4.70017 |
0.466 |
|
| 2024 |
Ellingson BM, Sanvito F, Cloughesy TF, Huang RY, Villanueva-Meyer JE, Pope WB, Barboriak DP, Shankar LK, Smits M, Kaufmann TJ, Boxerman JL, Weller M, Galanis E, Groot J, Gilbert MR, et al. A Neuroradiologist's Guide to Operationalizing the Response Assessment in Neuro-Oncology (RANO) Criteria Version 2.0 for Gliomas in Adults. Ajnr. American Journal of Neuroradiology. PMID 38926092 DOI: 10.3174/ajnr.A8396 |
0.304 |
|
| 2024 |
Price M, Neff C, Nagarajan N, Kruchko C, Waite KA, Cioffi G, Cordeiro BB, Willmarth N, Penas-Prado M, Gilbert MR, Armstrong TS, Barnholtz-Sloan JS, Ostrom QT. CBTRUS Statistical Report: American Brain Tumor Association & NCI Neuro-Oncology Branch Adolescent and Young Adult Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020. Neuro-Oncology. 26: iii1-iii53. PMID 38709657 DOI: 10.1093/neuonc/noae047 |
0.517 |
|
| 2024 |
Rogers JL, Wall T, Acquaye-Mallory AA, Boris L, Kim Y, Aldape K, Quezado MM, Butman JA, Smirniotopoulos JG, Chaudhry H, Tsien CI, Chittiboina P, Zaghloul K, Aboud O, Avgeropoulos NG, ... ... Gilbert MR, et al. Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors. Journal of Neuro-Oncology. PMID 38427131 DOI: 10.1007/s11060-024-04613-6 |
0.497 |
|
| 2024 |
Briceno N, Vera E, Komlodi-Pasztor E, Abdullaev Z, Choi A, Grajkowska E, Kunst T, Levine J, Lindsley M, Fernandez K, Reyes J, Boris L, Burton E, Panzer M, Polskin L, ... ... Gilbert MR, et al. Long-term survivors of glioblastoma: Tumor molecular, clinical, and imaging findings. Neuro-Oncology Advances. 6: vdae019. PMID 38420614 DOI: 10.1093/noajnl/vdae019 |
0.481 |
|
| 2023 |
Li A, Hancock JC, Quezado M, Ahn S, Briceno N, Celiku O, Ranjan S, Aboud O, Colwell N, Kim SA, Nduom E, Kuhn S, Park DM, Vera E, Aldape K, ... ... Gilbert MR, et al. TGF-β and BMP signaling are associated with the transformation of glioblastoma to gliosarcoma and then osteosarcoma. Neuro-Oncology Advances. 6: vdad164. PMID 38292240 DOI: 10.1093/noajnl/vdad164 |
0.447 |
|
| 2023 |
Byrne EM, Pascoe M, Cooper D, Armstrong TS, Gilbert MR. Challenges and limitations of clinical trials in the adolescent and young adult CNS cancer population: A systematic review. Neuro-Oncology Advances. 6: vdad159. PMID 38250563 DOI: 10.1093/noajnl/vdad159 |
0.455 |
|
| 2023 |
Price M, Neff C, Kruchko C, Barnholtz-Sloan JS, Cordeiro BB, Penas-Prado M, Ozer BH, Cimino PJ, Gilbert MR, Armstrong TS, Ostrom QT. Capturing evolving definitions of 12 select rare CNS tumors: a timely report from CBTRUS and NCI-CONNECT. Journal of Neuro-Oncology. 165: 279-290. PMID 37980692 DOI: 10.1007/s11060-023-04480-7 |
0.517 |
|
| 2023 |
Adegbesan KA, Tomassoni Ardori F, Yanpallewar S, Bradley SP, Chudasama Y, Vera E, Briceno N, King AL, Tessarollo L, Gilbert MR, Guedes VA, Smart DK, Armstrong TS, Shuboni-Mulligan DD. The sex-dependent impact of PER2 polymorphism on sleep and activity in a novel mouse model of cranial-irradiation-induced hypersomnolence. Neuro-Oncology Advances. 5: vdad108. PMID 37781088 DOI: 10.1093/noajnl/vdad108 |
0.458 |
|
| 2023 |
Kim Y, Gilbert MR, Armstrong TS, Celiku O. Clinical outcome assessment trends in clinical trials-Contrasting oncology and non-oncology trials. Cancer Medicine. PMID 37421295 DOI: 10.1002/cam4.6325 |
0.488 |
|
| 2023 |
Gondi V, Deshmukh S, Brown PD, Wefel JS, Armstrong TS, Tome WA, Gilbert MR, Konski A, Robinson CG, Bovi JA, Benzinger TLS, Roberge D, Kundapur V, Kaufman I, Shah S, et al. Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms with Hippocampal Avoidance during Whole-Brain Radiotherapy for Brain Metastases: Final Results of NRG Oncology CC001. International Journal of Radiation Oncology, Biology, Physics. PMID 37150264 DOI: 10.1016/j.ijrobp.2023.04.030 |
0.492 |
|
| 2023 |
King AL, Acquaye-Mallory AA, Vera E, Mendoza T, Reyes J, Stockdill ML, Gilbert MR, Armstrong TS. Feasibility and preliminary efficacy of a virtual reality intervention targeting distress and anxiety in primary brain tumor patients at the time of clinical evaluation: Study protocol for a phase 2 clinical trial. Bmc Cancer. 23: 262. PMID 36944930 DOI: 10.1186/s12885-023-10671-2 |
0.545 |
|
| 2023 |
King AL, Roche KN, Leeper HE, Vera E, Mendoza T, Mentges K, Acquaye-Mallory AA, Adegbesan KA, Boris L, Burton E, Choi A, Grajkowska E, Kunst T, Levine J, Lollo N, ... ... Gilbert MR, et al. Feasibility of a virtual reality intervention targeting distress and anxiety symptoms in patients with primary brain tumors: Interim analysis of a phase 2 clinical trial. Journal of Neuro-Oncology. PMID 36884201 DOI: 10.1007/s11060-023-04271-0 |
0.535 |
|
| 2023 |
King AL, Acquaye AA, Mendoza T, Reyes J, Stockdill M, Gilbert MR, Armstrong TS, Vera E. Feasibility and preliminary efficacy of a virtual reality intervention targeting distress and anxiety in primary brain tumor patients at the time of clinical evaluation: Study protocol for a phase 2 clinical trial. Research Square. PMID 36865245 DOI: 10.21203/rs.3.rs-2521990/v1 |
0.522 |
|
| 2023 |
King AL, Roche KN, Leeper HE, Vera E, Mendoza T, Mentges K, Acquaye AA, Adegbesan K, Boris L, Burton E, Choi A, Grajkowska E, Kunst T, Levine J, Lollo N, ... ... Gilbert MR, et al. Feasibility of a virtual reality intervention targeting distress and anxiety symptoms in patients with primary brain tumors: Interim analysis of a phase 2 clinical trial. Research Square. PMID 36789426 DOI: 10.21203/rs.3.rs-2522094/v1 |
0.525 |
|
| 2023 |
Kim Y, Armstrong TS, Gilbert MR, Celiku O. A Critical Analysis of Neuro-Oncology Clinical Trials. Neuro-Oncology. PMID 36757281 DOI: 10.1093/neuonc/noad036 |
0.438 |
|
| 2023 |
Leeper HE, Vera E, Christ A, Acquaye A, Briceno N, Choi A, Grajkowska E, Jammula V, Levine J, Lindsley M, Reyes J, Roche KN, Rogers JL, Timmer M, Boris L, ... ... Gilbert MR, et al. Association of Employment Status With Symptom Burden and Health-Related Quality of Life in People Living With Primary CNS Tumors. Neurology. PMID 36754634 DOI: 10.1212/WNL.0000000000207082 |
0.526 |
|
| 2023 |
Frederico SC, Vera E, Abdullaev Z, Acquaye A, Aldape K, Boris L, Briceno N, Choi A, Christ A, Cooper D, Grajkowska E, Kunst T, Leeper HE, Levine J, Lollo N, ... ... Gilbert MR, et al. Heterogeneous clinicopathological findings and patient-reported outcomes in adults with -altered CNS tumors: A case report and systematic literature review. Frontiers in Oncology. 13: 1099618. PMID 36741001 DOI: 10.3389/fonc.2023.1099618 |
0.543 |
|
| 2023 |
Jenkins S, Zhang W, Steinberg SM, Nousome D, Houston N, Wu X, Armstrong TS, Burton E, Smart D, Shah R, Peer CJ, Mozarsky B, Arisa O, Figg WD, Mendoza TR, ... ... Gilbert MR, et al. Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36705597 DOI: 10.1158/1078-0432.CCR-22-0855 |
0.439 |
|
| 2023 |
Liu Y, Chou FJ, Lang F, Zhang M, Song H, Zhang W, Davis DL, Briceno NJ, Zhang Y, Cimino PJ, Zaghloul KA, Gilbert MR, Armstrong TS, Yang C. Protein kinase B (PKB/AKT) protects IDH-mutated glioma from ferroptosis via Nrf2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36648507 DOI: 10.1158/1078-0432.CCR-22-3179 |
0.403 |
|
| 2022 |
Bergsneider BH, Vera E, Gal O, Christ A, King AL, Acquaye A, Choi A, Leeper HE, Mendoza T, Boris L, Burton E, Lollo N, Panzer M, Penas-Prado M, Pillai T, ... ... Gilbert MR, et al. Discovery of clinical and demographic determinants of symptom burden in primary brain tumor patients using network analysis and unsupervised clustering. Neuro-Oncology Advances. 5: vdac188. PMID 36820236 DOI: 10.1093/noajnl/vdac188 |
0.509 |
|
| 2022 |
King AL, Shuboni-Mulligan DD, Vera E, Crandon S, Acquaye AA, Boris L, Burton E, Choi A, Christ A, Grajkowska E, Jammula V, Leeper HE, Lollo N, Penas-Prado M, Reyes J, ... ... Gilbert MR, et al. Exploring the prevalence and burden of sleep disturbance in primary brain tumor patients. Neuro-Oncology Practice. 9: 526-535. PMID 36388423 DOI: 10.1093/nop/npac049 |
0.499 |
|
| 2022 |
Vera E, Christ A, Grajkowska E, Briceno N, Choi A, Crandon SK, Wall K, Lindsley M, Leeper HE, Levine J, Reyes J, Acquaye AA, King AL, Jammula V, Roche K, ... ... Gilbert MR, et al. Relationship between RANO-PRO Working Group standardised priority constructs and disease progression among malignant glioma patients: A retrospective cohort study. Eclinicalmedicine. 55: 101718. PMID 36386035 DOI: 10.1016/j.eclinm.2022.101718 |
0.504 |
|
| 2022 |
Ruiz-Rodado V, Dowdy T, Lita A, Kramp T, Zhang M, Shuboni-Mulligan D, Herold-Mende C, Armstrong TS, Gilbert MR, Camphausen K, Larion M. Metabolic biomarkers of radiotherapy response in plasma and tissue of an IDH1 mutant astrocytoma mouse model. Frontiers in Oncology. 12: 979537. PMID 36353533 DOI: 10.3389/fonc.2022.979537 |
0.507 |
|
| 2022 |
Scheurer ME, Zhou R, Gilbert MR, Bondy ML, Sulman EP, Yuan Y, Liu Y, Vera E, Wendland MM, Youssef EF, Stieber VW, Komaki RR, Flickinger JC, Kenyon LC, Robins HI, et al. Germline polymorphisms in associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825. Neuro-Oncology Advances. 4: vdac152. PMID 36299794 DOI: 10.1093/noajnl/vdac152 |
0.487 |
|
| 2022 |
Jammula V, Rogers JL, Vera E, Christ A, Leeper HE, Acquaye A, Briceno N, Choi A, Grajkowska E, Levine JE, Lindsley M, Reyes J, Roche KN, Timmer M, Boris L, ... ... Gilbert MR, et al. The Montreal Cognitive Assessment (MoCA) in neuro-oncology: A pilot study of feasibility and utility in telehealth and in-person clinical assessments. Neuro-Oncology Practice. 9: 429-440. PMID 36124322 DOI: 10.1093/nop/npac038 |
0.43 |
|
| 2022 |
Sass D, Vera E, Choi A, Acquaye A, Briceno N, Christ A, Grajkowska E, Jammula V, Levine J, Lindsley M, Reyes J, Roche K, Rogers JL, Timmer M, Boris L, ... ... Gilbert MR, et al. Evaluation of the key geriatric assessment constructs in primary brain tumor population - a descriptive study. Journal of Geriatric Oncology. PMID 36041994 DOI: 10.1016/j.jgo.2022.08.013 |
0.482 |
|
| 2022 |
Merchant M, Raygada M, Pang Y, Quezado M, Raffeld M, Xi L, Kim J, Tyagi M, Abdullaev Z, Kim O, Sergi Z, Pillai T, Ozer B, Zaghloul K, Heiss JD, ... ... Gilbert MR, et al. Case report: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, associated with a germline mutation in . Frontiers in Oncology. 12: 954879. PMID 35982947 DOI: 10.3389/fonc.2022.954879 |
0.467 |
|
| 2022 |
Lassman AB, Pugh SL, Wang TJC, Aldape K, Gan HK, Preusser M, Vogelbaum MA, Sulman EP, Won M, Zhang P, Moazami G, Macsai MS, Gilbert MR, Bain EE, Blot V, et al. Depatuxizumab-mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial. Neuro-Oncology. PMID 35849035 DOI: 10.1093/neuonc/noac173 |
0.41 |
|
| 2022 |
Shuboni-Mulligan DD, Young D, De La Cruz Minyety J, Briceno N, Celiku O, King AL, Munasinghe J, Wang H, Adegbesan KA, Gilbert MR, Smart DK, Armstrong TS. Histological analysis of sleep and circadian brain circuitry in cranial radiation-induced hypersomnolence (C-RIH) mouse model. Scientific Reports. 12: 11131. PMID 35778467 DOI: 10.1038/s41598-022-15074-0 |
0.432 |
|
| 2022 |
Woodford R, Prather L, Helfer C, Davey L, Penas-Prado M, Armstrong T, Tucker K, Aldape K, Gilbert M, Clark C, Thavaneswaran S, Wang D, Mandel J, Kasherman L. Malignant melanocytic schwannian tumor and leptomeningeal disease: A case series with a focus on management. Journal of the Neurological Sciences. 438: 120291. PMID 35635863 DOI: 10.1016/j.jns.2022.120291 |
0.458 |
|
| 2022 |
Pratt D, Lucas CG, Selvam PP, Abdullaev Z, Ketchum C, Quezado M, Armstrong TS, Gilbert MR, Papanicolau-Sengos A, Raffeld M, Choo-Wosoba H, Chan P, Whipple N, Nasrallah M, Santi M, et al. Recurrent ACVR1 mutations in posterior fossa ependymoma. Acta Neuropathologica. PMID 35587280 DOI: 10.1007/s00401-022-02435-2 |
0.388 |
|
| 2022 |
Kim Y, Armstrong TS, Gilbert MR, Celiku O. Accrual and access to neuro-oncology trials in the United States. Neuro-Oncology Advances. 4: vdac048. PMID 35571987 DOI: 10.1093/noajnl/vdac048 |
0.392 |
|
| 2022 |
Komlodi-Pasztor E, Gilbert MR, Armstrong TS. Diagnosis and Management of Stroke in Adults with Primary Brain Tumor. Current Oncology Reports. PMID 35543860 DOI: 10.1007/s11912-022-01280-6 |
0.483 |
|
| 2022 |
Leeper HE, Tonorezos E, Mayer D, Bakitas M, Chang S, Cooley ME, Hervey-Jumper S, Miaskowski C, Sherwood P, Tsien C, Wallgren K, Willmarth N, Arons D, Acquaye A, King AL, ... ... Gilbert MR, et al. Proceedings of the Survivorship Care in Neuro-Oncology Workshop sponsored by the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT). Neuro-Oncology Advances. 4: vdac029. PMID 35542753 DOI: 10.1093/noajnl/vdac029 |
0.448 |
|
| 2022 |
Pratt D, Abdullaev Z, Papanicolau-Sengos A, Ketchum C, Panneer Selvam P, Chung HJ, Lee I, Raffeld M, Gilbert MR, Armstrong TS, Pytel P, Borys E, Klonoski JM, McCord M, Horbinski C, et al. High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13. Acta Neuropathologica. PMID 35103816 DOI: 10.1007/s00401-022-02404-9 |
0.503 |
|
| 2021 |
Walker JG, Armstrong TS, O'Brien BJ, Gilbert MR, Casarez RL, Fagundes C, Heijnen CJ, Andersen CR, Yuan Y, Wu J, LoBiondo-Wood G. Associations of meaning of illness with psychosocial, clinical, and immunological characteristics in patients with Leptomeningeal metastasis. Comprehensive Psychoneuroendocrinology. 8: 100099. PMID 35757676 DOI: 10.1016/j.cpnec.2021.100099 |
0.451 |
|
| 2021 |
Yu G, Pang Y, Merchant M, Kesserwan C, Gangalapudi V, Abdelmaksoud A, Ranjan A, Kim O, Wei JS, Chou HC, Wen X, Sindiri S, Song YK, Xi L, Kaplan RN, ... ... Gilbert MR, et al. Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas. Cancers. 13. PMID 34885201 DOI: 10.3390/cancers13236092 |
0.469 |
|
| 2021 |
Armstrong TS, Gilbert MR. Clinical trial challenges, design considerations, and outcome measures in rare CNS tumors. Neuro-Oncology. 23: S30-S38. PMID 34725696 DOI: 10.1093/neuonc/noab209 |
0.506 |
|
| 2021 |
Jammula VR, Leeper H, Gilbert MR, Cooper D, Armstrong TS. Effects of Cognitive Reserve on Cognition in Individuals With Central Nervous System Disease. Cognitive and Behavioral Neurology : Official Journal of the Society For Behavioral and Cognitive Neurology. PMID 34508028 DOI: 10.1097/WNN.0000000000000282 |
0.418 |
|
| 2021 |
Pang Y, Yu G, Butler M, Sindiri S, Song YK, Wei JS, Wen X, Chou HC, Quezado M, Pack S, Xi L, Abdullaev Z, Kim O, Ranjan A, Merchant M, ... ... Gilbert MR, et al. Report of Canonical - Fusion in Glioblastoma. Jco Precision Oncology. 5. PMID 34485806 DOI: 10.1200/PO.20.00519 |
0.403 |
|
| 2021 |
Sievers P, Henneken SC, Blume C, Sill M, Schrimpf D, Stichel D, Okonechnikov K, Reuss DE, Benzel J, Maaß KK, Kool M, Sturm D, Zheng T, Ghasemi DR, Kohlhof-Meinecke P, ... ... Gilbert MR, et al. Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. Acta Neuropathologica. PMID 34355256 DOI: 10.1007/s00401-021-02356-6 |
0.518 |
|
| 2021 |
Al Feghali KA, Randall JW, Liu DD, Wefel JS, Brown PD, Grosshans DR, McAvoy SA, Farhat MA, Li J, McGovern SL, McAleer MF, Ghia AJ, Paulino AC, Sulman EP, Penas-Prado M, ... ... Gilbert MR, et al. Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessment. Neuro-Oncology Advances. 3: vdab073. PMID 34337411 DOI: 10.1093/noajnl/vdab073 |
0.492 |
|
| 2021 |
Rogers JL, Vera E, Acquaye A, Briceno N, Jammula V, King AL, Leeper H, Quezado MM, Gonzalez Alarcon J, Boris L, Burton E, Celiku O, Choi A, Christ A, Crandon S, ... ... Gilbert MR, et al. Living with a central nervous system (CNS) tumor: findings on long-term survivorship from the NIH Natural History Study. Neuro-Oncology Practice. 8: 460-474. PMID 34277024 DOI: 10.1093/nop/npab022 |
0.513 |
|
| 2021 |
Dirven L, Vos ME, Walbert T, Armstrong TS, Arons D, van den Bent MJ, Blakeley J, Brown PD, Bulbeck H, Chang SM, Coens C, Gilbert MR, Grant R, Jalali R, Leach D, et al. Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative. Neuro-Oncology Practice. 8: 417-425. PMID 34277020 DOI: 10.1093/nop/npab013 |
0.52 |
|
| 2021 |
Ranjan A, Pang Y, Butler M, Merchant M, Kim O, Yu G, Su YT, Gilbert MR, Levens D, Wu J. Targeting CDK9 for the Treatment of Glioblastoma. Cancers. 13. PMID 34207158 DOI: 10.3390/cancers13123039 |
0.301 |
|
| 2021 |
De La Cruz Minyety J, Shuboni-Mulligan DD, Briceno N, Young D, Gilbert MR, Celiku O, Armstrong TS. Association of Circadian Clock Gene Expression with Glioma Tumor Microenvironment and Patient Survival. Cancers. 13. PMID 34199348 DOI: 10.3390/cancers13112756 |
0.596 |
|
| 2021 |
Withrow DR, Devesa SS, Deapen D, Petkov V, Van Dyke AL, Adamo M, Armstrong TS, Gilbert MR, Linet MS. Nonmalignant meningioma and vestibular schwannoma incidence trends in the United States, 2004-2017. Cancer. PMID 34160068 DOI: 10.1002/cncr.33553 |
0.38 |
|
| 2021 |
Shuboni-Mulligan DD, Young DL, De La Cruz Minyety J, Vera E, Munasinghe J, Gall AJ, Gilbert MR, Armstrong TS, Smart DK. Impact of age on the circadian visual system and the sleep-wake cycle in mus musculus. Npj Aging and Mechanisms of Disease. 7: 10. PMID 33947857 DOI: 10.1038/s41514-021-00063-w |
0.398 |
|
| 2021 |
Wu J, Yuan Y, Long Priel DA, Fink D, Peer CJ, Sissung TM, Su YT, Pang Y, Yu G, Butler MK, Mendoza TR, Vera E, Ahmad S, Bryla C, Lindsley M, ... ... Gilbert MR, et al. Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33785481 DOI: 10.1158/1078-0432.CCR-20-4730 |
0.483 |
|
| 2021 |
Brown PD, Chung C, Liu DD, McAvoy S, Grosshans D, Al Feghali K, Mahajan A, Li J, McGovern SL, McAleer MF, Ghia AJ, Sulman EP, Penas-Prado M, de Groot JF, Heimberger AB, ... ... Gilbert MR, et al. A Prospective Phase II Randomized Trial of Proton Radiotherapy vs. Intensity Modulated Radiotherapy for Patients with Newly Diagnosed Glioblastoma. Neuro-Oncology. PMID 33647972 DOI: 10.1093/neuonc/noab040 |
0.472 |
|
| 2021 |
Baroni L, Sundaresan L, Heled A, Coltin H, Pajtler KW, Lin T, Merchant TE, McLendon R, Faria C, Buntine M, White CL, Pfister SM, Gilbert MR, Armstrong TS, Bouffet E, et al. Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. Neuro-Oncology. PMID 33580238 DOI: 10.1093/neuonc/noab034 |
0.38 |
|
| 2021 |
Wefel JS, Armstrong TS, Pugh SL, Gilbert MR, Wendland MM, Brachman DG, Roof KS, Brown PD, Crocker IR, Robins HI, Hunter G, Won M, Mehta MP. Neurocognitive, Symptom, and Health- Related Quality of Life Outcomes of a Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma (NRG/RTOG 0825). Neuro-Oncology. PMID 33515019 DOI: 10.1093/neuonc/noab011 |
0.495 |
|
| 2020 |
Yu G, Butler MK, Abdelmaksoud A, Pang Y, Su YT, Rae Z, Dadkhah K, Kelly MC, Song YK, Wei JS, Terabe M, Atony R, Mentges K, Theeler BJ, Penas-Prado M, ... ... Gilbert MR, et al. Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post Immunotherapy. Frontiers in Oncology. 10: 601452. PMID 33520712 DOI: 10.3389/fonc.2020.601452 |
0.548 |
|
| 2020 |
Penas-Prado M, Wu J, Cahill DP, Brat DJ, Costello JF, Kluetz PG, Cairncross JG, van den Bent M, Verhaak RGW, Aboud O, Burger P, Chang SM, Cordova C, Huang RY, Rowe LS, ... ... Gilbert MR, et al. Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Oligodendroglioma Workshop. Neuro-Oncology Advances. 2: vdz048. PMID 33289010 DOI: 10.1093/noajnl/vdz048 |
0.526 |
|
| 2020 |
Penas-Prado M, Armstrong TS, Gilbert MR. Proposed Additions to the NCCN Guidelines for Adult Medulloblastoma. Journal of the National Comprehensive Cancer Network : Jnccn. 18: 1579-1584. PMID 33152706 DOI: 10.6004/jnccn.2020.7650 |
0.538 |
|
| 2020 |
Gilbert MR, Yuan Y, Wu J, Mendoza T, Vera E, Omuro A, Lieberman F, Robins HI, Gerstner ER, Wu J, Wen PY, Mikkelsen T, Aldape K, Armstrong TS. A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma. Neuro-Oncology. PMID 33085768 DOI: 10.1093/neuonc/noaa240 |
0.486 |
|
| 2020 |
Leggiero NM, Armstrong TS, Gilbert MR, King AL. Use of virtual reality for symptom management in solid-tumor patients with implications for primary brain tumor research: a systematic review. Neuro-Oncology Practice. 7: 477-489. PMID 33014388 DOI: 10.1093/Nop/Npaa012 |
0.591 |
|
| 2020 |
Penas-Prado M, Theeler BJ, Cordeiro B, Dunkel IJ, Hau P, Mahajan A, Robinson GW, Willmarth N, Aboud O, Aldape K, Butman JA, Gajjar A, Kelly W, Rao G, Raygada M, ... ... Gilbert MR, et al. Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Adult Medulloblastoma Workshop. Neuro-Oncology Advances. 2: vdaa097. PMID 33005896 DOI: 10.1093/noajnl/vdaa097 |
0.492 |
|
| 2020 |
Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Bullard DE, Mehta MP, Gilbert MR, Brown PD, Stelzer KJ, McElroy JP, Fleming JL, Timmers CD, Becker AP, Salavaggione AL, et al. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902983. PMID 32706640 DOI: 10.1200/Jco.19.02983 |
0.354 |
|
| 2020 |
Lynes J, Acquaye AA, Sur H, Nwankwo A, Sanchez V, Vera E, Wu T, Theeler B, Armstrong TS, Gilbert MR, Nduom EK. Variations in attitudes towards stereotactic biopsy of adult diffuse midline glioma patients: a survey of members of the AANS/CNS Tumor Section. Journal of Neuro-Oncology. PMID 32705457 DOI: 10.1007/S11060-020-03585-7 |
0.532 |
|
| 2020 |
Theeler BJ, Dalal Y, Monje M, Shilatifard A, Suvà ML, Aboud O, Camphausen K, Cordova C, Finch E, Heiss JD, Packer RJ, Romo CG, Aldape K, Penas-Prado M, Armstrong T, ... Gilbert MR, et al. NCI-CONNECT: Comprehensive Oncology Network Evaluating Rare CNS Tumors-Histone Mutated Midline Glioma Workshop Proceedings. Neuro-Oncology Advances. 2: vdaa007. PMID 32642676 DOI: 10.1093/noajnl/vdaa007 |
0.494 |
|
| 2020 |
Raffeld M, Abdullaev Z, Pack SD, Xi L, Nagaraj S, Briceno N, Vera E, Pittaluga S, Lopes Abath Neto O, Quezado M, Aldape K, Armstrong TS, Gilbert MR. High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma. Acta Neuropathologica Communications. 8: 101. PMID 32641156 DOI: 10.1186/S40478-020-00973-Y |
0.503 |
|
| 2020 |
Ruiz-Rodado V, Seki T, Dowdy T, Lita A, Zhang M, Han S, Yang C, Cherukuri MK, Gilbert MR, Larion M. Metabolic Landscape of a Genetically Engineered Mouse Model of IDH1 Mutant Glioma. Cancers. 12. PMID 32575619 DOI: 10.3390/Cancers12061633 |
0.334 |
|
| 2020 |
Boxerman JL, Quarles CC, Hu LS, Erickson BJ, Gerstner ER, Smits M, Kaufmann TJ, Barboriak DP, Huang RH, Wick W, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, ... ... Gilbert MR, et al. Consensus Recommendations for a Dynamic Susceptibility Contrast MRI Protocol for Use in High-Grade Gliomas. Neuro-Oncology. PMID 32516388 DOI: 10.1093/Neuonc/Noaa141 |
0.313 |
|
| 2020 |
Ellison DW, Aldape KD, Capper D, Fouladi M, Gilbert MR, Gilbertson RJ, Hawkins C, Merchant T, Pajtler K, Venneti S, Louis DN. cIMPACT-NOW Update 7: advancing the molecular classification of ependymal tumors. Brain Pathology (Zurich, Switzerland). PMID 32502305 DOI: 10.1111/Bpa.12866 |
0.358 |
|
| 2020 |
Rahman M, Sawyer WG, Lindhorst S, Deleyrolle LP, Harrison JK, Karachi A, Dastmalchi F, Flores-Toro J, Mitchell DA, Lim M, Gilbert MR, Reardon DA. Adult Immuno-Oncology: Using Past Failures to Inform the Future. Neuro-Oncology. PMID 32391559 DOI: 10.1093/Neuonc/Noaa116 |
0.328 |
|
| 2020 |
Penas-Prado M, Armstrong TS, Gilbert MR. Letter to the Editor Re: Mohile et al. Neuro-Oncology. PMID 32343803 DOI: 10.1093/Neuonc/Noaa109 |
0.419 |
|
| 2020 |
Wen PY, Weller M, Lee EQ, Alexander BA, Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, Cloughesy TF, DeGroot JF, Galanis E, Gilbert MR, Hegi ME, et al. Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. Neuro-Oncology. PMID 32328653 DOI: 10.1093/Neuonc/Noaa106 |
0.356 |
|
| 2020 |
Zimmer AS, Steinberg SM, Smart DD, Gilbert MR, Armstrong TS, Burton E, Houston N, Biassou N, Gril B, Brastianos PK, Carter S, Lyden D, Lipkowitz S, Steeg PS. Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases. Future Oncology (London, England). PMID 32270710 DOI: 10.2217/Fon-2020-0094 |
0.533 |
|
| 2020 |
Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Vera E, Wu J, Xu J, Giglio P, Colman H, Walbert T, Raizer J, Groves MD, Tran D, Iwamoto F, Avgeropoulos N, ... ... Gilbert MR, et al. A Bayesian Adaptive Randomized Phase II Multicenter Trial of Bevacizumab with or without Vorinostat in Adults with Recurrent Glioblastoma. Neuro-Oncology. PMID 32166308 DOI: 10.1093/Neuonc/Noaa062 |
0.53 |
|
| 2020 |
Kelly WJ, Gilbert MR. Glucocorticoids and immune checkpoint inhibitors in glioblastoma. Journal of Neuro-Oncology. PMID 32108294 DOI: 10.1007/S11060-020-03439-2 |
0.37 |
|
| 2020 |
Rowe L, Vera E, Acquaye A, Crandon S, Shah V, Bryla C, Wu J, Wall K, Siegel C, Reyes J, Penas-Prado M, Leggiero N, Cordova C, Burton E, Antony R, ... ... Gilbert M, et al. The prevalence of altered body image in patients with primary brain tumors: an understudied population. Journal of Neuro-Oncology. PMID 32096067 DOI: 10.1007/S11060-020-03433-8 |
0.567 |
|
| 2020 |
Dirks PB, Gilbert MR, Holland EC, Maher EA, Weiss WA. Translating basic science discoveries into improved outcomes for glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32060102 DOI: 10.1158/1078-0432.Ccr-19-3924 |
0.319 |
|
| 2020 |
Brown PD, Gondi V, Pugh S, Tome WA, Wefel JS, Armstrong TS, Bovi JA, Robinson C, Konski A, Khuntia D, Grosshans D, Benzinger TLS, Bruner D, Gilbert MR, Roberge D, et al. Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902767. PMID 32058845 DOI: 10.1200/Jco.19.02767 |
0.522 |
|
| 2020 |
Kelly WJ, Giles AJ, Gilbert M. T lymphocyte-targeted immune checkpoint modulation in glioma. Journal For Immunotherapy of Cancer. 8. PMID 32051289 DOI: 10.1136/Jitc-2019-000379 |
0.4 |
|
| 2020 |
Armstrong TS, Dirven L, Arons D, Bates A, Chang SM, Coens C, Espinasse C, Gilbert MR, Jenkinson D, Kluetz P, Mendoza T, Rubinstein L, Sul J, Weller M, Wen PY, et al. Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report. The Lancet. Oncology. 21: e97-e103. PMID 32007210 DOI: 10.1016/S1470-2045(19)30796-X |
0.559 |
|
| 2020 |
Lee EQ, Weller M, Sul J, Bagley SJ, Sahebjam S, van den Bent M, Ahluwalia M, Campian JL, Galanis E, Gilbert MR, Holdhoff M, Lesser GJ, Lieberman FS, Mehta MP, Penas-Prado M, et al. Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. Neuro-Oncology. PMID 31974566 DOI: 10.1093/Neuonc/Noaa015 |
0.345 |
|
| 2020 |
Theeler BJ, Jung J, Burton E, Gonzalez J, Leeper H, Wu J, Nduom E, Zaghloul K, Ray-Chaudhury A, Quezado M, Raffeld M, Allen JE, Prabhu VV, Stogniew M, Oster W, ... ... Gilbert MR, et al. A first-in-human phase I single-agent dose-escalation, food effect and dose expansion study of oral ONC206 in recurrent and rare primary central nervous system neoplasms. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps2576 |
0.483 |
|
| 2020 |
Zimmer ADS, Steinberg SM, Smart DK, Gilbert MR, Armstrong T, Burton E, Houston ND, Biassou N, Gril B, Brastianos PK, Carter SL, Lyden D, Lipkowitz S, Steeg PS. Phase I/II study of T-DM1 alone versus T-DM1 and metronomic temozolomide in secondary prevention of HER2-positive breast cancer brain metastases following stereotactic radiosurgery. Journal of Clinical Oncology. 38: TPS2572-TPS2572. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps2572 |
0.376 |
|
| 2020 |
DeMaria PJ, Bilusic M, Park D, Heery CR, Madan RA, Strauss J, Donahue RN, Marte J, Gilbert MR, Steinberg SM, Schlom J, Gulley JL. A randomized, double-blind, phase II clinical trial of GI-6301 (yeast-brachyury vaccine) versus placebo in combination with standard of care definitive radiotherapy in locally advanced, unresectable, chordoma. Journal of Clinical Oncology. 38: 11527-11527. DOI: 10.1200/Jco.2020.38.15_Suppl.11527 |
0.306 |
|
| 2020 |
Prabhu VV, Morrow S, Cuoco CA, Kawakibi AR, Jung J, Madhukar N, Garnett MJ, McDermott U, Benes CH, Wechsler-Reya R, Anantharaman L, Charter N, Rucker JB, Doranz BJ, Basken J, ... ... Gilbert MR, et al. Abstract 5688: IND-enabling characterization of ONC206 as the next bitopic antagonist for oncology Cancer Research. 80: 5688-5688. DOI: 10.1158/1538-7445.Am2020-5688 |
0.318 |
|
| 2019 |
Zhou Y, Liu Y, Zhang J, Yu D, Li A, Song H, Zhang W, Davis D, Gilbert MR, Liu F, Yang C. Autocrine BMP4 Signaling Enhances Tumor Aggressiveness via Promoting Wnt/β-Catenin Signaling in IDH1-mutant Gliomas. Translational Oncology. 13: 125-134. PMID 31865175 DOI: 10.1016/J.Tranon.2019.10.019 |
0.329 |
|
| 2019 |
Celiku O, Gilbert MR, Lavi O. Computational modeling demonstrates that glioblastoma cells can survive spatial environmental challenges through exploratory adaptation. Nature Communications. 10: 5704. PMID 31836713 DOI: 10.1038/S41467-019-13726-W |
0.315 |
|
| 2019 |
Robins HI, Eickhoff J, Gilbert MR, Armstrong TS, Shi W, De Groot JF, Schultz CJ, Hunter GK, Valeinis E, Roach M, Youssef EF, Souhami L, Howard SP, Lieberman FS, Herman JG, et al. The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525. Neuro-Oncology Practice. 6: 473-478. PMID 31832217 DOI: 10.1093/Nop/Npz006 |
0.492 |
|
| 2019 |
Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, Anderson KJ, Abiola O, Aldape K, Alfaro KD, Alpar D, Amin SB, Ashley DM, Bandopadhayay P, Barnholtz-Sloan JS, ... ... Gilbert MR, et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature. PMID 31748746 DOI: 10.1038/S41586-019-1775-1 |
0.353 |
|
| 2019 |
Shuboni-Mulligan DD, Breton G, Smart D, Gilbert M, Armstrong TS. Radiation chronotherapy-clinical impact of treatment time-of-day: a systematic review. Journal of Neuro-Oncology. PMID 31729636 DOI: 10.1007/S11060-019-03332-7 |
0.556 |
|
| 2019 |
Victor RR, Malta TM, Seki T, Lita A, Dowdy T, Celiku O, Cavazos-Saldana A, Li A, Liu Y, Han S, Zhang W, Song H, Davis D, Lee S, Trepel JB, ... ... Gilbert MR, et al. Metabolic Reprogramming Associated with Aggressiveness Occurs in the G-CIMP-High Molecular Subtypes of IDH1mut Lower Grade Gliomas. Neuro-Oncology. PMID 31665443 DOI: 10.1093/Neuonc/Noz207 |
0.327 |
|
| 2019 |
Penas-Prado M, Armstrong TS, Gilbert MR. Progress in rare central nervous system tumors. Current Opinion in Neurology. PMID 31577601 DOI: 10.1097/Wco.0000000000000755 |
0.568 |
|
| 2019 |
Burton E, Yusuf M, Gilbert MR, Gaskins J, Woo S. Failure to complete standard radiation therapy in glioblastoma patients: Patterns from a national database with implications for survival and therapeutic decision making in older glioblastoma patients. Journal of Geriatric Oncology. PMID 31521589 DOI: 10.1016/J.Jgo.2019.08.014 |
0.355 |
|
| 2019 |
Jung J, Zhang Y, Celiku O, Zhang W, Song H, Williams BJ, Giles AJ, Rich JN, Abounader R, Gilbert MR, Park DM. Mitochondrial NIX Promotes Tumor Survival in the Hypoxic Niche of Glioblastoma. Cancer Research. PMID 31488423 DOI: 10.1158/0008-5472.Can-19-0198 |
0.348 |
|
| 2019 |
Acquaye AA, Payén SS, Vera E, Williams LA, Gilbert MR, Weathers SP, Armstrong TS. Identifying symptom recurrences in primary brain tumor patients using the MDASI-BT and qualitative interviews. Journal of Patient-Reported Outcomes. 3: 58. PMID 31444579 DOI: 10.1186/S41687-019-0143-0 |
0.554 |
|
| 2019 |
Molinari E, Mendoza TR, Gilbert MR. Opportunities and challenges of incorporating clinical outcome assessments in brain tumor clinical trials. Neuro-Oncology Practice. 6: 81-92. PMID 31386029 DOI: 10.1093/Nop/Npy032 |
0.406 |
|
| 2019 |
Lim-Fat MJ, Bi WL, Lo J, Lee EQ, Ahluwalia MS, Batchelor TT, Chang SM, Chiocca EA, Chukwueke U, Cloughesy TF, Colman H, Deangelis LM, Galanis E, Gilbert MR, De Groot JF, et al. Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Neurosurgery. PMID 31215634 DOI: 10.1093/Neuros/Nyz186 |
0.348 |
|
| 2019 |
Truitt G, Gittleman H, Leece R, Ostrom QT, Kruchko C, Armstrong TS, Gilbert MR, Barnholtz-Sloan JS. Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT. Journal of Neuro-Oncology. PMID 31209773 DOI: 10.1007/S11060-019-03215-X |
0.585 |
|
| 2019 |
Wang H, Cui J, Yang C, Rosenblum JS, Zhang Q, Song Q, Pang Y, Fang F, Sun M, Dmitriev P, Gilbert MR, Eisenhofer G, Pacak K, Zhuang Z. A Transgenic Mouse Model of Pacak⁻Zhuang Syndrome with An Gain-of-Function Mutation. Cancers. 11. PMID 31091718 DOI: 10.3390/Cancers11050667 |
0.307 |
|
| 2019 |
Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, Jones DTW, Joyce JA, Kearns P, Kieran MW, Mellinghoff IK, et al. Challenges to curing primary brain tumours. Nature Reviews. Clinical Oncology. PMID 30733593 DOI: 10.1038/S41571-019-0177-5 |
0.321 |
|
| 2019 |
Gilbert MR, Loghin M. The Treatment of Malignant Gliomas. Current Treatment Options in Neurology. 7: 293-303. PMID 15967092 DOI: 10.1007/S11940-005-0039-6 |
0.458 |
|
| 2019 |
Wu J, Yuan Y, Cordova C, Aboud O, Penas-Prado M, Theeler BJ, Bryla C, Su Y, Grajkowska E, McCoy A, Boris L, Siegel C, Antony R, Garren N, Lawhon T, ... ... Gilbert MR, et al. Phase I trial of TG02 plus dose-dense or metronomic temozolomide for recurrent anaplastic astrocytoma and glioblastoma in adults. Journal of Clinical Oncology. 37: 2031-2031. DOI: 10.1200/Jco.2019.37.15_Suppl.2031 |
0.52 |
|
| 2019 |
Ratnam NM, Sonnemann HM, Gilbert MR, Giles AJ. Abstract 1188: Reversing epigenetic gene silencing to overcome immune evasion in CNS malignancies Cancer Research. 79: 1188-1188. DOI: 10.1158/1538-7445.Am2019-1188 |
0.343 |
|
| 2019 |
Cordova C, Vera E, Aboud O, Antony R, Boris L, Bryla C, Burton E, Crandon S, Leggiero N, Reyes J, Siegel C, Theeler B, Vyas Y, Wall K, Wu J, ... Gilbert M, et al. RARE-35. MRI FINDINGS AT PROGRESSION IN ADULT PATIENTS WITH MEDULLOBLASTOMA Neuro-Oncology. 21: vi229-vi229. DOI: 10.1093/Neuonc/Noz175.958 |
0.485 |
|
| 2019 |
Siegel C, Raygada M, Acquaye A, Stearn S, Wall K, Crandon S, Stevens-Brown K, Wu J, Vera L, Theeler B, Reyes J, Leggiero N, Cordova C, Bryla C, Burton E, ... ... Gilbert M, et al. RARE-10. IMPROVING CARE FOR ADULT PATIENTS WITH RARE CNS TUMORS: THE NATIONAL CANCER INSTITUTE-COMPREHENSIVE ONCOLOGY NETWORK EVALUATING RARE CNS TUMORS (NCI-CONNECT) PROGRAM AND CLINIC Neuro-Oncology. 21: vi223-vi223. DOI: 10.1093/Neuonc/Noz175.933 |
0.604 |
|
| 2019 |
King A, Leggiero N, Acquaye A, Vera E, Crandon S, Gilbert M, Armstrong T. RBTT-03. USE OF VIRTUAL REALITY ENVIRONMENTS TO IMPROVE SELF-REPORTED DISTRESS, MOOD DISTURBANCE AND OVERALL SYMPTOM BURDEN USING CORRELATIVE STRESS BIOMARKERS IN PRIMARY BRAIN TUMOR (PBT) PATIENTS Neuro-Oncology. 21: vi219-vi219. DOI: 10.1093/Neuonc/Noz175.915 |
0.547 |
|
| 2019 |
Randall J, Al Feghali K, Wefel J, Grosshans D, Dibaj S, Milton D, McAvoy S, Li J, McGovern S, McAleer M, Ghia A, Paulino A, Sulman E, Penas-Prado M, Wang J, ... ... Gilbert M, et al. RTHP-18. PROSPECTIVE PHASE II RANDOMIZED TRIAL COMPARING PROTON THERAPY VS. PHOTON IMRT FOR NEWLY DIAGNOSED GBM: SECONDARY ANALYSIS COMPARISON OF GENDER AND NEUTROPHIL-LYMPHOCYTE RATIO (NLR) IN GBM OUTCOMES Neuro-Oncology. 21: vi213-vi213. DOI: 10.1093/Neuonc/Noz175.889 |
0.519 |
|
| 2019 |
Yusuf M, Gaskins J, Gilbert M, Woo S, Burton E. Rthp-08. Failure To Complete Standard Radiation Therapy In Glioblastoma Patients: Patterns From A National Database With Implications For Survival And Therapeutic Decision Making Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.881 |
0.304 |
|
| 2019 |
Young D, Dee Smart D, King A, Gilbert M, Armstrong T, Shuboni-Mulligan D. RDNA-13. DOSE RESPONSE CURVE FOR RADIATION-INDUCED HYPERSOMNOLENCE (RIH) IN A MOUSE MODEL OF CRANIAL RADIATION: BEHAVIORAL ANALYSIS OF SLEEP AND ACTIVITY Neuro-Oncology. 21: vi209-vi209. DOI: 10.1093/Neuonc/Noz175.872 |
0.516 |
|
| 2019 |
Shuboni-Mulligan D, Dahut M, Young D, Gilbert M, Armstrong T. RDNA-04. CIRCADIAN RHYTHMS AND RADIATION CHRONOTHERAPY IN GLIOBLASTOMA CELL LINES AND CENTRAL NERVOUS SYSTEM CELL CONTROLS Neuro-Oncology. 21: vi207-vi207. DOI: 10.1093/Neuonc/Noz175.864 |
0.497 |
|
| 2019 |
King A, Shuboni-Mulligan D, Vera E, Crandon S, Aboud O, Antony R, Boris L, Bryla C, Burton E, Cordova C, Gartland C, Grajkowska E, Penas-Prado M, Reyes J, Leggiero N, ... ... Gilbert M, et al. QOLP-36. THE IMPORTANCE OF SLEEP DISTURBANCE IN PRIMARY BRAIN TUMOR (PBT) PATIENTS: CLINICAL CHARACTERISTICS & CO-OCCURRENCE WITH TUMOR-RELATED & PSYCHOLOGICAL SYMPTOMS Neuro-Oncology. 21: vi205-vi206. DOI: 10.1093/Neuonc/Noz175.856 |
0.562 |
|
| 2019 |
Leggiero N, Armstrong T, Vera E, Gilbert M, King A. QOLP-28. THE USE OF VIRTUAL REALITY FOR SYMPTOM MANAGEMENT: APPLICATION IN NEURO-ONCOLOGY Neuro-Oncology. 21: vi203-vi204. DOI: 10.1093/Neuonc/Noz175.848 |
0.58 |
|
| 2019 |
Acquaye A, Wall K, Gilbert M, Armstrong T. QOLP-08. UNDERSTANDING THE EXPERIENCE OF YOUNG ADULTS (YAS) DIAGNOSED WITH AN EPENDYMOMA FROM THE ADULT EPENDYMOMA OUTCOMES PROJECT AND RARE CNS OUTCOMES AND RISK STUDY Neuro-Oncology. 21: vi199-vi199. DOI: 10.1093/Neuonc/Noz175.828 |
0.581 |
|
| 2019 |
Aboud O, Gilbert M, Armstrong T, Vera E, Wu J, Wall K, Theeler B, Siegel C, Reyes J, Leggiero N, Crandon S, Cordova C, Boris L, Bryla C, Burton E, et al. NIMG-32. CHALLENGES OF IMAGING INTERPRETATION TO PREDICT OLIGODENDROGLIOMA GRADE Neuro-Oncology. 21: vi168-vi168. DOI: 10.1093/Neuonc/Noz175.702 |
0.528 |
|
| 2019 |
Al Feghali K, Randall J, Wefel J, Guha-Thakurta N, Grosshans D, Dibaj S, McAvoy S, Li J, McGovern S, McAleer M, Ghia A, Paulino A, Sulman E, Penas-Prado M, Wang J, ... ... Gilbert M, et al. NIMG-03. PROSPECTIVE PHASE II RANDOMIZED TRIAL COMPARING PROTON THERAPY VS. PHOTON IMRT FOR GBM: SECONDARY ANALYSIS COMPARISON OF PROGRESSION FREE SURVIVAL BETWEEN RANO VS. CLINICAL AND RADIOLOGICAL ASSESSMENT Neuro-Oncology. 21: vi161-vi162. DOI: 10.1093/Neuonc/Noz175.675 |
0.582 |
|
| 2019 |
Briceno N, Abdullaev Z, Vera E, Blumental De Abreu F, Quezado M, Pack S, Xi L, Raffeld M, Gilbert M, Aldape K, Armstrong T. PATH-20. INVESTIGATION OF CLINICALLY AGGRESSIVE SPINAL CORD EPENDYMOMA THROUGH METHYLATION ANALYSIS Neuro-Oncology. 21: vi147-vi147. DOI: 10.1093/Neuonc/Noz175.616 |
0.554 |
|
| 2019 |
Vera E, Gilbert M, Aboud O, Antony R, Boris L, Bryla C, Burton E, Cordova C, Crandon S, Leggiero N, Penas-Prado M, Reyes J, Siegel C, Theeler B, Wall K, et al. HOUT-22. EVALUATING CLINICAL IMPACT UTILIZING THE RANO-PRO COLLABORATIVE’S STANDARDIZED PRIORITY CONSTRUCTS Neuro-Oncology. 21: vi116-vi117. DOI: 10.1093/Neuonc/Noz175.487 |
0.559 |
|
| 2019 |
Vyas Y, Vera E, Bryla C, Crandon S, Wu J, Wall K, Theeler B, Siegel C, Reyes J, Penas-Prado M, Leggiero N, Cordova C, Burton E, Antony R, Boris L, ... ... Gilbert M, et al. HOUT-04. ASSOCIATION OF COMMON PATIENT-REPORTED IMMUNOTHERAPY SYMPTOMATIC SIDE EFFECTS AND PSEUDOPROGRESSION IN PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS Neuro-Oncology. 21: vi112-vi112. DOI: 10.1093/Neuonc/Noz175.469 |
0.603 |
|
| 2019 |
Mendoza T, Rowe L, Vera E, Acquaye A, Gilbert M, Armstrong T. HOUT-01. ALOPECIA SYMPTOM IMPACT SCALE (ASIS): MEASURING THE SYMPTOMS OF ALOPECIA AND THEIR IMPACT IN PATIENTS WITH PRIMARY BRAIN TUMORS Neuro-Oncology. 21: vi111-vi112. DOI: 10.1093/Neuonc/Noz175.466 |
0.571 |
|
| 2019 |
Su Y, Butler M, Hwang L, Maric D, Earp S, Terabe M, Gilbert M, Wu J. EXTH-44. INHIBITION OF MerTK ACTIVATES GLIOBLASTOMA-ASSOCIATED MACROPHAGES AND INDUCES TUMOR CELL DEATH IN GLIOMA MICROENVIRONMENT Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.376 |
0.314 |
|
| 2019 |
Wu J, Bryla C, Su Y, Grajkowska E, McCoy A, Boris L, Antony R, Garren N, Siegel C, Cordova C, Aboud O, Vera E, Lawhon T, Penas-Prado M, Theeler B, ... ... Gilbert M, et al. ACTR-62. PHASE I TRIAL OF TG02 PLUS DOSE-DENSE OR METRONOMIC TEMOZOLOMIDE FOR RECURRENT HIGH-GRADE ASTROCYTOMA IN ADULTS Neuro-Oncology. 21: vi27-vi28. DOI: 10.1093/Neuonc/Noz175.104 |
0.525 |
|
| 2019 |
Armstrong T, Deshmukh S, Brown P, Gondi V, Benzinger T, Gilbert M, Tome W, Wefel J, Bruner D, Roberge D, Kundapur V, Devisetty K, Shah S, Usuki K, Baschnagel A, et al. ACTR-50. PRESERVATION OF NEUROCOGNITIVE FUNCTION & PATIENT-REPORTED SYMPTOMS WITH HIPPOCAMPAL AVOIDANCE (HA) DURING WHOLE-BRAIN RADIOTHERAPY (WBRT) FOR BRAIN METASTASES: LONG-TERM RESULTS OF NRG ONCOLOGY CC001 Neuro-Oncology. 21: vi24-vi25. DOI: 10.1093/Neuonc/Noz175.092 |
0.562 |
|
| 2019 |
Lassman A, Pugh S, Wang T, Aldape K, Gan H, Preusser M, Vogelbaum M, Sulman E, Won M, Zhang P, Moazami G, Macsai M, Gilbert M, Bain E, Blot V, et al. ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM) Neuro-Oncology. 21: vi17-vi17. DOI: 10.1093/Neuonc/Noz175.064 |
0.329 |
|
| 2019 |
Al Feghali K, Randall J, Wefel J, Guha-Thakurta N, Grosshans D, Dibej S, McAvoy S, Li J, McGovern S, McAleer M, Ghia A, Paulino A, Sulman E, Penas-Prado M, Wang J, ... ... Gilbert M, et al. Prospective Phase II Randomized Trial Comparing Proton Therapy vs. IMRT for Newly Diagnosed GBM: Secondary Analysis Comparison of Progression Free Survival between Clinical Radiological Assessment vs. Response Assessment in Neuro-Oncology (RANO) International Journal of Radiation Oncology*Biology*Physics. 105: S139. DOI: 10.1016/J.Ijrobp.2019.06.132 |
0.533 |
|
| 2018 |
Cachia D, Johnson DR, Kaufmann TJ, Lowe S, Andersen S, Olar A, Cooper SL, Frankel BM, Gilbert MR. Case-based review: ependymomas in adults. Neuro-Oncology Practice. 5: 142-153. PMID 31386035 DOI: 10.1093/Nop/Npy026 |
0.334 |
|
| 2018 |
Armstrong TS, Vera E, Zhou R, Acquaye AA, Sullaway CM, Berger AM, Breton G, Mahajan A, Wefel JS, Gilbert MR, Bondy M, Scheurer ME. Association of genetic variants with fatigue in patients with malignant glioma. Neuro-Oncology Practice. 5: 122-128. PMID 31386001 DOI: 10.1093/Nop/Npx020 |
0.54 |
|
| 2018 |
Vera E, Acquaye AA, Mendoza TR, Gilbert MR, Armstrong TS. Relationship between symptom burden and health status: analysis of the MDASI-BT and EQ-5D. Neuro-Oncology Practice. 5: 56-63. PMID 31385972 DOI: 10.1093/Nop/Npx010 |
0.519 |
|
| 2018 |
Hegi ME, Genbrugge E, Gorlia T, Stupp R, Gilbert MR, Chinot OL, Nabors LB, Jones G, van Criekinge W, Straub J, Weller M. MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide. A Pooled Analysis of Four Clinical Trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30514777 DOI: 10.1158/1078-0432.Ccr-18-3181 |
0.326 |
|
| 2018 |
Barboriak DP, Zhang Z, Desai P, Snyder BS, Safriel Y, McKinstry RC, Bokstein F, Sorensen G, Gilbert MR, Boxerman JL. Interreader Variability of Dynamic Contrast-enhanced MRI of Recurrent Glioblastoma: The Multicenter ACRIN 6677/RTOG 0625 Study. Radiology. 181296. PMID 30480488 DOI: 10.1148/Radiol.2019181296 |
0.311 |
|
| 2018 |
Koehler JW, Miller AD, Miller CR, Porter B, Aldape K, Beck J, Brat D, Cornax I, Corps K, Frank C, Giannini C, Horbinski C, Huse JT, O'Sullivan MG, Rissi DR, ... ... Gilbert MR, et al. A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human Glioma. Journal of Neuropathology and Experimental Neurology. PMID 30239918 DOI: 10.1093/Jnen/Nly085 |
0.361 |
|
| 2018 |
Lynes J, Jackson S, Sanchez V, Dominah G, Wang X, Kuek A, Hayes CP, Benzo S, Scott GC, Chittiboina P, Zaghloul KA, Park DM, Wu J, Hourigan CS, Giles AJ, ... ... Gilbert MR, et al. Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade. Neurosurgery. PMID 30189044 DOI: 10.1093/Neuros/Nyy392 |
0.372 |
|
| 2018 |
Cavalli FMG, Hübner JM, Sharma T, Luu B, Sill M, Zapotocky M, Mack SC, Witt H, Lin T, Shih DJH, Ho B, Santi M, Emery L, Hukin J, Dunham C, ... ... Gilbert MR, et al. Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica. PMID 30019219 DOI: 10.1007/S00401-018-1888-X |
0.549 |
|
| 2018 |
Ratnam NM, Gilbert MR, Giles AJ. Immunotherapy in CNS Cancers: the Role of Immune Cell Trafficking. Neuro-Oncology. PMID 29771386 DOI: 10.1093/Neuonc/Noy084 |
0.332 |
|
| 2018 |
Hall WA, Pugh SL, Wefel JS, Armstrong TS, Gilbert MR, Brachman DG, Werner-Wasik M, Wendland MM, Brown PD, Chao ST, Roof KS, Robins HI, Mehta MP, Curran WJ, Movsas B. Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes. Neurosurgery. PMID 29618054 DOI: 10.1093/Neuros/Nyy003 |
0.549 |
|
| 2018 |
Boxerman JL, Zhang Z, Safriel Y, Rogg JM, Wolf RL, Mohan S, Marques H, Sorensen AG, Gilbert MR, Barboriak DP. Prognostic Value of Contrast Enhancement and FLAIR for Survival in Newly Diagnosed Glioblastoma Treated With and Without Bevacizumab: Results from ACRIN 6686. Neuro-Oncology. PMID 29590461 DOI: 10.1093/Neuonc/Noy049 |
0.368 |
|
| 2018 |
Ranjan S, Quezado M, Garren N, Boris L, Siegel C, Lopes Abath Neto O, Theeler BJ, Park DM, Nduom E, Zaghloul KA, Gilbert MR, Wu J. Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases. Bmc Cancer. 18: 239. PMID 29490632 DOI: 10.1186/S12885-018-4131-1 |
0.369 |
|
| 2018 |
Blumenthal DT, Won M, Mehta MP, Gilbert MR, Brown PD, Bokstein F, Brachman DG, Werner-Wasik M, Hunter GK, Valeinis E, Hopkins K, Souhami L, Howard SP, Lieberman FS, Shrieve DC, et al. Short delay in initiation of radiotherapy for patients with glioblastoma- effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group (RTOG) database. Neuro-Oncology. PMID 29462493 DOI: 10.1093/Neuonc/Noy017 |
0.384 |
|
| 2018 |
Jackson S, Weingart J, Nduom EK, Harfi TT, George RT, McAreavey D, Ye X, Anders NM, Peer C, Figg WD, Gilbert M, Rudek MA, Grossman SA. The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids and Barriers of the Cns. 15: 2. PMID 29332604 DOI: 10.1186/S12987-017-0088-8 |
0.35 |
|
| 2018 |
Sloan AE, Gilbert MR, Zhang P, Aldape KD, Wu J, Rogers LR, Wen PY, Barani IJ, Iwamoto FM, Raval RR, Voloschin AD, Groot JFD, Won M, Mehta MP. NRG BN002: Phase I study of checkpoint inhibitors anti-CTLA-4, anti-PD-1, the combination in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology. 36: 2053-2053. DOI: 10.1200/Jco.2018.36.15_Suppl.2053 |
0.341 |
|
| 2018 |
Maraka S, Groves MD, Mammoser AG, Melguizo-Gavilanes I, Conrad CA, Tremont-Lukats I, Loghin ME, O'Brien BJ, Puduvalli VK, Sulman EP, Hess KR, Aldape KD, Gilbert MR, De Groot JF, Yung WKA, et al. Phase I factorial study of temozolomide plus memantine, mefloquine, and metformin as post-radiation adjuvant therapy for newly diagnosed glioblastoma. Journal of Clinical Oncology. 36: 2044-2044. DOI: 10.1200/Jco.2018.36.15_Suppl.2044 |
0.361 |
|
| 2018 |
Giles AJ, Hutchinson MNM, Sonnemann H, Reid CM, Jung J, Zhang W, Song H, Bailey R, Davis D, Park DM, Roederer M, Gilbert MR. Abstract A11: Ipilimumab protects T cells from the antiproliferative effects of dexamethasone Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-A11 |
0.318 |
|
| 2018 |
Zimmer A, Gril B, Steinberg S, Smart D, Gilbert M, Armstrong T, Xiao L, Houston N, Biassou N, Brastianos P, Carter S, Lyden D, Lipkowitz S, Steeg P. Abstract OT2-06-01: Phase I/II study of T-DM1 alone versus T-DM1 and metronomic temozolomide in secondary prevention of HER2-Positive breast cancer brain metastases following stereotactic radiosurgery Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Ot2-06-01 |
0.368 |
|
| 2018 |
Aboud O, Raffeld M, Brown J, Sabersky A, Briceno N, Brown M, Chung H, Crandon S, Ji M, Levine J, Patel S, Reyes J, Siegel C, Vera E, Xi L, ... ... Gilbert M, et al. RARE-26. MUTATIONS IN MAPK PATHWAY GENES ARE CHARACTERISTIC AND CONFIRMATORY OF MULTINODULAR AND VACUOLATING NEURONAL TUMOR OF THE CEREBRUM Neuro-Oncology. 20: vi241-vi241. DOI: 10.1093/Neuonc/Noy148.999 |
0.496 |
|
| 2018 |
Armstrong T, Yuan Y, Wu J, Mendoza T, Vera E, Omuro A, Lieberman F, Robins H, Gerstner E, Wu J, Wen P, Mikkelsen T, Aldape K, Gilbert M. RARE-24. OBJECTIVE RESPONSE AND CLINICAL BENEFIT IN RECURRENT EPENDYMOMA IN ADULTS: FINAL REPORT OF CERN 08-02: A PHASE II STUDY OF DOSE-DENSE TEMOZOLOMIDE AND LAPATINIB Neuro-Oncology. 20: vi241-vi241. DOI: 10.1093/Neuonc/Noy148.998 |
0.514 |
|
| 2018 |
Boris L, Bryla C, Vera E, Aboud O, Garren N, Park D, Siegel C, Theeler B, Wu J, Armstrong T, Gilbert M. RARE-21. A DESCRIPTIVE REPORT OF PATIENTS WITH RARE CENTRAL NERVOUS SYSTEM (CNS) CANCERS ON AN NCI-CONNECT CANCER MOONSHOT IMMUNE CHECKPOINT INHIBITOR TRIAL Neuro-Oncology. 20: vi240-vi240. DOI: 10.1093/Neuonc/Noy148.995 |
0.512 |
|
| 2018 |
Garren N, Vera E, Aboud O, Acquaye A, Boris L, Brown M, Crandon S, Ji M, Levine J, Reyes J, Romo C, Siegel C, Wu J, Gilbert M, Armstrong T. QOLP-26. PATIENT REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS) SCREENING FOR ANXIETY & DEPRESSION IN CENTRAL NERVOUS SYSTEM(CNS) CANCER: LARGE COHORT REPORT FROM THE NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS). Neuro-Oncology. 20: vi220-vi220. DOI: 10.1093/Neuonc/Noy148.912 |
0.501 |
|
| 2018 |
Acquaye A, Vera E, Aboud O, Armstrong T, Boris L, Brown M, Crandon S, Garren N, Ji M, Levine J, Romo C, Reyes J, Siegel C, Wu J, Mackey M, ... ... Gilbert M, et al. QOLP-16. CAPTURING THE PRIMARY BRAIN TUMOR (PBT) PATIENT’S EXPERIENCE OF BODY IMAGE DISSATISFACTION: REPORT FROM THE NEURO-ONCOLOGY BRANCH-NATURAL HISTORY STUDY (NOB-NHS) Neuro-Oncology. 20: vi217-vi218. DOI: 10.1093/Neuonc/Noy148.902 |
0.537 |
|
| 2018 |
Acquaye A, Armstrong T, Vera E, Crandon S, Fletcher Ruiz M, Aboud O, Boris L, Brown M, Garren N, Ji M, Levine J, Romo C, Reyes J, Siegel C, Wu J, ... Gilbert M, et al. QOLP-14. PRELIMINARY EXAMINATION OF CONFIRMED GLIOMA RISK FACTORS AMONG EPENDYMOMA PATIENTS IN THE NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS) AND RISK AND OUTCOMES STUDY (ROS) Neuro-Oncology. 20: vi217-vi217. DOI: 10.1093/Neuonc/Noy148.900 |
0.5 |
|
| 2018 |
Mathen P, Armstrong T, Vera E, Acquaye A, Crandon S, Fletcher Ruiz M, Aboud O, Boris L, Brown M, Garren N, Ji M, Levine J, Mackey M, Romo C, Reyes J, ... ... Gilbert M, et al. QOLP-09. ASSOCIATION BETWEEN BODY IMAGE INVESTMENT AND ALTERATION IN PATIENTS WITH PRIMARY BRAIN TUMORS Neuro-Oncology. 20: vi216-vi216. DOI: 10.1093/Neuonc/Noy148.895 |
0.559 |
|
| 2018 |
Rowe L, Vera E, Acquaye A, Crandon S, Fletcher Ruiz M, Aboud O, Boris L, Brown M, Garren N, Ji M, Levine J, Mackey M, Mathan P, Romo C, Reyes J, ... ... Gilbert M, et al. QOLP-06. BODY IMAGE DISTURBANCE IN PATIENTS WITH PRIMARY BRAIN TUMORS Neuro-Oncology. 20: vi215-vi215. DOI: 10.1093/Neuonc/Noy148.892 |
0.557 |
|
| 2018 |
Gondi V, Pugh S, D Brown P, Wefel J, Gilbert M, Bovi J, Robinson C, Tammie B, Tome W, Armstrong T, Bruner D, Khuntia D, Grosshans D, Konski A, Robidoux A, et al. NCOG-01. PRESERVATION OF NEUROCOGNITIVE FUNCTION (NCF) WITH HIPPOCAMPAL AVOIDANCE DURING WHOLE-BRAIN RADIOTHERAPY (WBRT) FOR BRAIN METASTASES: PRELIMINARY RESULTS OF PHASE III TRIAL NRG ONCOLOGY CC001 Neuro-Oncology. 20: vi172-vi172. DOI: 10.1093/Neuonc/Noy148.716 |
0.537 |
|
| 2018 |
Siegel C, Aboud O, Brown M, Chung H, Raffeld M, Crandon S, Ji M, Levine J, Vera E, Patel S, Reyes J, Armstrong T, Xi L, Acquaye A, Boris L, ... ... Gilbert M, et al. PATH-52. UTILIZING NEXT GENERATION SEQUENCING REPORTS IN CLINICAL DECISION MAKING: REPORT FROM THE NATIONAL INSTITUTES OF HEALTH (NIH) NEURO-ONCOLOGY BRANCH (NOB) NATURAL HISTORY STUDY (NHS) PRIMARY BRAIN TUMOR PANEL (PBTP) Neuro-Oncology. 20: vi170-vi170. DOI: 10.1093/Neuonc/Noy148.706 |
0.534 |
|
| 2018 |
Schreck K, Vera E, Aboud O, Acquaye A, Boris L, Briceno N, Brown M, Chung H, Crandon S, Garren N, Ji M, Levine J, Patel S, Quezado M, Raffeld M, ... ... Gilbert M, et al. PATH-28. THE NATURAL HISTORY OF BRAF V600E-MUTATED GLIOBLASTOMAS IN ADULTS Neuro-Oncology. 20: vi164-vi164. DOI: 10.1093/Neuonc/Noy148.684 |
0.457 |
|
| 2018 |
Briceno N, Crandon S, Vera E, Siegel C, Aboud O, Brown M, Chung H, Ji M, Levine J, Patel S, Reyes J, Raffeld M, Gilbert M, Xi L, Armstrong T. INNV-43. NUCLEIC ACID ADEQUACY FROM ARCHIVED FORMALIN-FIXED PARAFFIN EMBEDDED (FFPE) TUMOR TISSUE FOR NEXT-GENERATION SEQUENCING (NGS) IN NATIONAL CANCER INSTITUTE (NCI)- NATURAL HISTORY STUDY (NHS) OF PRIMARY CNS TUMOR Neuro-Oncology. 20: vi146-vi146. DOI: 10.1093/Neuonc/Noy148.611 |
0.533 |
|
| 2018 |
Li X, Vera E, Gilbert M, Celiku O, Armstrong T. INNV-41. MY STORI -- A SYMPTOM TRACKING AND REPORTING INSTRUMENT MOBILE APPLICATION FOR CENTRAL NERVOUS SYSTEM CANCER PATIENTS Neuro-Oncology. 20: vi146-vi146. DOI: 10.1093/Neuonc/Noy148.609 |
0.51 |
|
| 2018 |
Giles A, Vézina A, Acquaye A, Ruiz MF, Aboud O, Hutchinson M, Lugo M, Reid C, Sonnemann H, Yang L, Gilbert M, Armstrong T. INNV-38. THE NEURO-ONCOLOGY BRANCH TRANSLATIONAL RESEARCH IMMERSION PROGRAM: RESULTS FROM TWO YEARS OF DEVELOPMENT AND PARTICIPANT FEEDBACK Neuro-Oncology. 20: vi145-vi146. DOI: 10.1093/Neuonc/Noy148.608 |
0.443 |
|
| 2018 |
Vera E, Levine J, Ji M, Grajkowska E, Crandon S, Gilbert M, Armstrong T. INNV-33. IMPLEMENTATION OF ELECTRONIC DATA CAPTURE FOR USE IN NATURAL HISTORY STUDIES: UTILITY OF CENTER FOR CANCER RESEARCHS (CCR) LABMATRIX AND SCRIBE SYSTEMS FOR THE NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS) Neuro-Oncology. 20: vi145-vi145. DOI: 10.1093/Neuonc/Noy148.604 |
0.456 |
|
| 2018 |
Giles A, Nettey L, Liechti T, Beddall M, Vera E, Park D, Wu J, Theeler B, Siegel C, Boris L, Garren N, Bryla C, McCoy A, Nduom E, Zaghloul K, ... ... Gilbert M, et al. IMMU-68. SINGLE-CELL PROTEOMIC ANALYSIS OF IMMUNE CELL RESPONSE TO CHECKPOINT BLOCKADE USING 30-PARAMETER FLOW CYTOMETRY Neuro-Oncology. 20: vi137-vi137. DOI: 10.1093/Neuonc/Noy148.571 |
0.439 |
|
| 2018 |
Crandon S, Vera E, Acquaye A, Siegel C, Aboud O, Boris L, Brown M, Garren N, Ji M, Levine J, Romo C, Reyes J, Wu J, Gilbert M, Armstrong T. HOUT-12. CHARACTERIZATION OF SYMPTOM BURDEN IN MINORITY PATIENTS WITH CNS TUMORS: A REPORT FROM THE NEURO-ONCOLOGY BRANCH (NOB) NATURAL HISTORY STUDY (NHS) Neuro-Oncology. 20: vi115-vi115. DOI: 10.1093/Neuonc/Noy148.480 |
0.58 |
|
| 2018 |
Ruiz MF, Vera E, Acquaye A, Boris L, Brown M, Crandon S, Garren N, Ji M, Levine J, Reyes J, Siegel C, Wu J, Gilbert M, Armstrong T. HOUT-03. SCREENING FOR MOOD DISTURBANCE IN LONG-TERM CENTRAL NERVOUS SYSTEM (CNS) TUMOR SURVIVORS USING PATIENT REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS): A NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS) REPORT Neuro-Oncology. 20: vi113-vi113. DOI: 10.1093/Neuonc/Noy148.471 |
0.538 |
|
| 2018 |
Truitt G, Gittleman H, Ostrom Q, Kruchko C, Boscia A, Armstrong T, Gilbert M, Barnholtz-Sloan J. EXTH-61. PARTNERSHIP FOR DEFINING THE IMPACT OF 12 SELECT RARE CNS TUMORS: A REPORT FROM CBTRUS AND THE NCI-CONNECT Neuro-Oncology. 20: vi98-vi98. DOI: 10.1093/Neuonc/Noy148.408 |
0.544 |
|
| 2018 |
Su Y, Phan F, Hwang L, Earp HS, Gilbert M, Wu J. TMIC-32. INHIBITION OF MerTK MODULATES GLIOMA-ASSOCIATED MACROPHAGES AND MICROGLIA IN TUMOR MICROENVIRONMENT Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.1091 |
0.324 |
|
| 2018 |
Puduvalli V, Wu J, Yuan Y, Armstrong T, Wu J, Giglio P, Xu J, Colman H, Walbert T, Raizer J, Groves M, Iwamoto F, Tran D, Avgeropoulos N, Paleologos N, ... ... Gilbert M, et al. ACTR-13. A BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB VERSUS BEVACIZUMAB PLUS VORINOSTAT IN ADULTS WITH RECURRENT GLIOBLASTOMA FINAL RESULTS Neuro-Oncology. 20: vi13-vi13. DOI: 10.1093/Neuonc/Noy148.047 |
0.565 |
|
| 2017 |
Yust Katz S, Cachia D, Kamiya-Matsuoka C, Olar A, Theeler B, Penas Prado M, Gilbert MR, Armstrong T. Corrigendum to 'Ependymomas arising outside of the central nervous system: A case series and literature review' [J Clin Neurosci 47 (2018) 202-207]. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. PMID 29295763 DOI: 10.1016/J.Jocn.2017.12.011 |
0.46 |
|
| 2017 |
Hao S, Song H, Zhang W, Seldomridge A, Jung J, Giles AJ, Hutchinson MK, Cao X, Colwell N, Lita A, Larion M, Maric D, Abu-Asab M, Quezado M, Kramp T, ... ... Gilbert MR, et al. Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma. Neuro-Oncology. PMID 29294092 DOI: 10.1093/Neuonc/Nox241 |
0.332 |
|
| 2017 |
Ho WSC, Sizdahkhani S, Hao S, Song H, Seldomridge A, Tandle A, Maric D, Kramp T, Lu R, Heiss JD, Camphausen K, Gilbert MR, Zhuang Z, Park DM. LB-100, a novel Protein Phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation. Cancer Letters. PMID 29199006 DOI: 10.1016/J.Canlet.2017.11.035 |
0.305 |
|
| 2017 |
Shi W, Scannell Bryan M, Gilbert MR, Mehta MP, Blumenthal DT, Brown PD, Valeinis E, Hopkins K, Souhami L, Andrews DW, Tzuk-Shina T, Howard SP, Youssef EF, Lessard N, Dignam JJ, et al. Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. International Journal of Radiation Oncology, Biology, Physics. PMID 29102648 DOI: 10.1016/J.Ijrobp.2017.08.038 |
0.355 |
|
| 2017 |
Yust Katz S, Cachia D, Kamiya Matsuok C, Olar A, Theeler B, Penas Prado M, Gilbert MR, Armstrong T. Ependymomas arising outside of the central nervous system: A case series and literature review. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. PMID 29054328 DOI: 10.1016/J.Jocn.2017.10.026 |
0.506 |
|
| 2017 |
Nghiemphu PL, Ebiana VA, Wen P, Gilbert M, Abrey LE, Lieberman F, DeAngelis LM, Robins HI, Yung WKA, Chang S, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, et al. Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. Journal of Neuro-Oncology. PMID 28988377 DOI: 10.1007/S11060-017-2624-4 |
0.374 |
|
| 2017 |
Jackson S, ElAli A, Virgintino D, Gilbert MR. Blood-brain barrier pericyte importance in malignant gliomas: what we can learn from stroke and Alzheimer's disease. Neuro-Oncology. PMID 28541444 DOI: 10.1093/Neuonc/Nox058 |
0.327 |
|
| 2017 |
Gittleman H, Lim D, Kattan MW, Chakravarti A, Gilbert MR, Lassman AB, Lo SS, Machtay M, Sloan AE, Sulman EP, Tian D, Vogelbaum MA, Wang TJC, Penas-Prado M, Youssef E, et al. An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Neuro-Oncology. 19: 669-677. PMID 28453749 DOI: 10.1093/Neuonc/Now208 |
0.389 |
|
| 2017 |
Blumenthal DT, Gorlia T, Gilbert MR, Kim MM, Burt Nabors L, Mason WP, Hegi ME, Zhang P, Golfinopoulos V, Perry JR, Hyun Nam D, Erridge SC, Corn BW, Mirimanoff RO, Brown PD, et al. Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro-Oncology. PMID 28371907 DOI: 10.1093/Neuonc/Nox025 |
0.304 |
|
| 2017 |
Colwell N, Larion M, Giles AJ, Seldomridge AN, Sizdahkhani S, Gilbert MR, Park DM. Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells. Neuro-Oncology. PMID 28339582 DOI: 10.1093/Neuonc/Now258 |
0.354 |
|
| 2017 |
Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, et al. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. Journal of Neuro-Oncology. PMID 28116649 DOI: 10.1007/S11060-016-2357-9 |
0.374 |
|
| 2017 |
Walker J, O’Brien BJ, Armstrong TS, Gilbert MR, Casarez R, Wood G. QLIF-45. ASSOCIATIONS AMONG MEANING OF ILLNESS, SYMPTOM BURDEN, QUALITY OF LIFE AND DEPRESSION IN PATIENTS WITH LEPTOMENINGEAL METASTASIS Neuro-Oncology. 19: vi211-vi211. DOI: 10.1093/Neuonc/Nox168.852 |
0.488 |
|
| 2017 |
Vera E, Mendoza T, Crandon S, Lisa B, Garren N, Siegel C, Park DM, Sul J, Theeler B, Wu J, Gilbert MR, Armstrong T. QLIF-31. SYMPTOM BURDEN AND HEALTH STATUS OF PATIENTS WITH RARE VERSUS COMMON BRAIN TUMORS Neuro-Oncology. 19: vi208-vi208. DOI: 10.1093/Neuonc/Nox168.840 |
0.571 |
|
| 2017 |
Acquaye AA, Garren N, Vera E, Lisa B, Siegel C, Park DM, Wu J, Crandon S, Theeler BJ, Sul J, Gilbert MR, Armstrong T. QLIF-17. ASSESSING DEPRESSION IN GLIOMA PATIENTS Neuro-Oncology. 19: vi204-vi205. DOI: 10.1093/Neuonc/Nox168.827 |
0.49 |
|
| 2017 |
Garren N, Acquaye AA, Vera E, Lisa B, Siegel C, Park DM, Sul J, Theeler BJ, Wu J, Crandon S, Gilbert M, Armstrong T. QLIF-13. EVALUATION OF ANXIETY SYMPTOMS AMONG BRAIN TUMOR PATIENTS; ARE WE PROVIDING APPROPRIATE, EFFECTIVE CARE? Neuro-Oncology. 19: vi203-vi204. DOI: 10.1093/Neuonc/Nox168.823 |
0.563 |
|
| 2017 |
Lisa B, Vera E, Wu J, Park DM, Bryla C, Crandon S, Garren N, McCoy A, Siegel C, Theeler BJ, Sul J, Gilbert M, Armstrong T. QLIF-03. UNUSUAL ADVERSE DRUG REACTIONS IN HIGH GRADE GLIOMA PATIENTS TREATED WITH TEMOZOLOMIDE Neuro-Oncology. 19: vi201-vi201. DOI: 10.1093/Neuonc/Nox168.814 |
0.507 |
|
| 2017 |
Siegel C, Armstrong T, Chung H, Crandon S, Patel S, Powers A, Quezado M, Ray-Chaudhury A, Vera E, Wu J, Xi L, Raffeld M, Gilbert M. PATH-40. STANDARDIZED MOLECULAR ANALYSIS OF PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS IN A RESEARCH BASED CLINICAL PRACTICE. AN INTRODUCTION TO THE PRIMARY CNS TUMOR NEXT GENERATION SEQUENCING (NGS) PANEL Neuro-Oncology. 19: vi179-vi180. DOI: 10.1093/Neuonc/Nox168.730 |
0.547 |
|
| 2017 |
Vogelbaum M, Swanson K, Zhang P, Cahill D, Hawkins-Daarud A, Gilbert MR, De Leon G, Rickertsen C, Kunkel L, Shi W, Penas-Prado M, Youssef E, Shu H, Wendland M, Suh J, et al. NIMG-77. IMPACT OF POST-SURGICAL ENHANCING TUMOR VOLUME AND T2/FLAIR VOLUME ON THE SURVIVAL IMPACT OF BEVACIZUMAB IN NRG ONCOLOGY/RTOG 0825 Neuro-Oncology. 19: vi159-vi160. DOI: 10.1093/Neuonc/Nox168.649 |
0.321 |
|
| 2017 |
Hutchinson M, Giles A, Sonnemann H, Reid C, Park DM, Gilbert MR. Immu-53. Co-Administration Of Dexamethasone With Checkpoint Blockade Therapy Increases Survival In Brain Tumor Model Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.511 |
0.37 |
|
| 2017 |
Jackson S, Weingart J, Nduom E, Holdhoff M, Blakeley J, Piotrowski AF, Abd T, George R, McAreavey D, Ye X, Anders N, Peer C, Barnes J, Figg W, Rudek M, ... Gilbert M, et al. ACTR-85. THE EFFECT OF REGADENOSON ON TEMOZOLOMIDE NEUROPHARMACOKINETICS IN GLIOBLASTOMA PATIENTS MEASURED BY INTRACEREBRAL MICRODIALYSIS Neuro-Oncology. 19: vi19-vi19. DOI: 10.1093/Neuonc/Nox168.071 |
0.314 |
|
| 2017 |
Chung C, Brown PD, McAvoy S, Grosshans DR, Dibaj S, Guha-Thakurta N, Li J, McGovern SL, Mcaleer MF, Ghia A, Paulino A, Sulman E, Penas-Prado M, Wang J, de Groot J, ... ... Gilbert MR, et al. ACTR-72. A PROSPECTIVE PHASE II RANDOMIZED TRIAL TO COMPARE INTENSITY MODULATED PROTON RADIOTHERAPY (IMPT) VS. INTENSITY MODULATED RADIOTHERAPY (IMRT) FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM) Neuro-Oncology. 19: vi16-vi16. DOI: 10.1093/Neuonc/Nox168.059 |
0.5 |
|
| 2017 |
Wu J, Bryla C, McCoy A, Lisa B, Garren N, Siegel C, Grajkowska E, Theeler B, Park DM, Parrott T, Armstrong TS, Yuan Y, Gilbert MR. ACTR-69. PHASE I TRIAL OF TG02 PLUS DOSE-DENSE OR METRONOMIC TEMOZOLOMIDE FOR ADULTS WITH RECURRENT ANAPLASTIC ASTROCYTOMA AND GLIOBLASTOMA Neuro-Oncology. 19: vi15-vi15. DOI: 10.1093/Neuonc/Nox168.056 |
0.51 |
|
| 2017 |
Krauze A, Myrehaug S, Chang M, Holdford D, Smith S, Shih J, Tofilon P, Fine H, Rowe L, Gilbert MR, Camphausen K. Actr-57. Does The Addition Of Valproic Acid To Concurrent Radiation Therapy And Temozolomide Improve Patient Outcome? – Correlative Analysis Of Rtog 0525, Seer And A Phase Ii Nci Trial Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.048 |
0.32 |
|
| 2017 |
Armstrong TS, Gilbert MR, Bondy M, Sulman E, Yuan Y, Zhou R, Vera E, Wendland M, Pugh S, Scheurer M. OS05.6 Final risk model for Temozolomide (TMZ)-Myelotoxicity in patients with Glioblastoma treated on NRG Oncology’s RTOG 0825 Neuro-Oncology. 19: iii10-iii10. DOI: 10.1093/Neuonc/Nox036.033 |
0.518 |
|
| 2017 |
Krauze AV, Myrehaug S, Chang MG, Holdford D, Smith S, Shih J, Tofilon P, Fine HA, Rowe L, Gilbert M, Camphausen KA. Does the Addition of Valproic Acid to Concurrent Radiation Therapy and Temozolomide Improve Patient Outcome? Correlative Analysis of RTOG 0525, SEER, and a Phase 2 NCI Trial International Journal of Radiation Oncology Biology Physics. 99. DOI: 10.1016/J.Ijrobp.2017.06.240 |
0.321 |
|
| 2016 |
Weathers SS, Gilbert MR. Toward Personalized Targeted Therapeutics: An Overview. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 27995437 DOI: 10.1007/S13311-016-0496-5 |
0.395 |
|
| 2016 |
Chang S, Zhang P, Cairncross JG, Gilbert MR, Bahary JP, Dolinskas CA, Chakravarti A, Aldape KD, Bell EH, Schiff D, Jaeckle K, Brown PD, Barger GR, Werner-Wasik M, Shih H, et al. Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. Neuro-Oncology. PMID 27994066 DOI: 10.1093/Neuonc/Now236 |
0.398 |
|
| 2016 |
Sulman EP, Ismaila N, Armstrong TS, Tsien C, Batchelor TT, Cloughesy T, Galanis E, Gilbert M, Gondi V, Lovely M, Mehta M, Mumber MP, Sloan A, Chang SM. Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016707562. PMID 27893327 DOI: 10.1200/Jco.2016.70.7562 |
0.539 |
|
| 2016 |
Gilbert MR, Pugh SL, Aldape K, Sorensen AG, Mikkelsen T, Penas-Prado M, Bokstein F, Kwok Y, Lee RJ, Mehta M. NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma. Journal of Neuro-Oncology. PMID 27770279 DOI: 10.1007/S11060-016-2288-5 |
0.336 |
|
| 2016 |
Acquaye AA, Vera E, Gilbert MR, Armstrong TS. Clinical presentation and outcomes for adult ependymoma patients. Cancer. PMID 27679985 DOI: 10.1002/Cncr.30355 |
0.561 |
|
| 2016 |
Gittleman H, Lim D, Kattan MW, Chakravarti A, Gilbert MR, Lassman AB, Lo SS, Machtay M, Sloan AE, Sulman EP, Tian D, Vogelbaum MA, Wang TJ, Penas-Prado M, Youssef E, et al. An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Neuro-Oncology. PMID 27663387 DOI: 10.1200/Jco.2016.34.15_Suppl.2007 |
0.389 |
|
| 2016 |
Ostrom QT, Gittleman H, Kruchko C, Louis DN, Brat DJ, Gilbert MR, Petkov VI, Barnholtz-Sloan JS. Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying). Journal of Neuro-Oncology. PMID 27418206 DOI: 10.1007/S11060-016-2217-7 |
0.376 |
|
| 2016 |
Weathers SP, Han X, Liu DD, Conrad CA, Gilbert MR, Loghin ME, O'Brien BJ, Penas-Prado M, Puduvalli VK, Tremont-Lukats I, Colen RR, Yung WK, de Groot JF. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. Journal of Neuro-Oncology. PMID 27406589 DOI: 10.1200/Jco.2015.33.15_Suppl.2005 |
0.348 |
|
| 2016 |
Armstrong TS, Shade MY, Breton G, Gilbert MR, Mahajan A, Scheurer ME, Vera E, Berger AM. Sleep-wake disturbance in patients with brain tumors. Neuro-Oncology. PMID 27286798 DOI: 10.1093/Neuonc/Now119 |
0.512 |
|
| 2016 |
Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, Jones DT, Luu B, Cavalli FM, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon RE, ... ... Gilbert MR, et al. Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27269943 DOI: 10.1200/Jco.2015.65.7825 |
0.475 |
|
| 2016 |
LeBlanc AK, Mazcko C, Brown DE, Koehler JW, Miller AD, Miller CR, Bentley RT, Packer RA, Breen M, Boudreau CE, Levine JM, Simpson RM, Halsey C, Kisseberth W, Rossmeisl JH, ... ... Gilbert MR, et al. Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients. Neuro-Oncology. PMID 27179361 DOI: 10.1093/Neuonc/Now051 |
0.386 |
|
| 2016 |
Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, Coons S, Ricci P, Bullard D, Brown PD, Stelzer K, Brachman D, Suh JH, Schultz CJ, Bahary JP, et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. The New England Journal of Medicine. 374: 1344-55. PMID 27050206 DOI: 10.1056/Nejmoa1500925 |
0.336 |
|
| 2016 |
Wu J, Armstrong TS, Gilbert MR. Biology and management of ependymomas. Neuro-Oncology. PMID 27022130 DOI: 10.1093/Neuonc/Now016 |
0.586 |
|
| 2016 |
Gilbert MR. Antiangiogenic Therapy for Glioblastoma: Complex Biology and Complicated Results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27001588 DOI: 10.1200/Jco.2016.66.5364 |
0.417 |
|
| 2016 |
Helfer JL, Wen PY, Blakeley J, Gilbert MR, Armstrong TS. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD). Neuro-Oncology. 18: ii26-ii36. PMID 26989130 DOI: 10.1093/Neuonc/Nov270 |
0.577 |
|
| 2016 |
Gilbert MR, Rubinstein L, Lesser G. Creating clinical trial designs that incorporate clinical outcome assessments. Neuro-Oncology. 18: ii21-ii25. PMID 26989129 DOI: 10.1093/Neuonc/Nov254 |
0.33 |
|
| 2016 |
Happold C, Gorlia T, Chinot O, Gilbert MR, Nabors LB, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, Reardon DA, Perry JR, Mehta MP, Stupp R, Weller M. Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26786929 DOI: 10.1200/Jco.2015.63.6563 |
0.353 |
|
| 2016 |
Zhou R, Scheurer ME, Gilbert MR, Bondy M, Sulman EP, Yuan Y, Liu Y, Vera E, Wendland MM, Brachman D, Bearden J, McGovern SL, Wilson SS, Judy KD, Robins HI, et al. Polymorphisms risk modeling for vascular toxicity in patients with glioblastoma treated on NRG Oncology/RTOG 0825. Journal of Clinical Oncology. 34: 2049-2049. DOI: 10.1200/Jco.2016.34.15_Suppl.2049 |
0.512 |
|
| 2016 |
Vera E, Scheurer ME, Zhou R, Acquaye AA, Sullaway CM, Berger AM, Breton G, Mahajan A, Wefel JS, Gilbert MR, Armstrong TS. Investigation of risk factors associated with fatigue in glioma patients. Journal of Clinical Oncology. 34: 2018-2018. DOI: 10.1200/Jco.2016.34.15_Suppl.2018 |
0.555 |
|
| 2016 |
Rowe L, Dong T, Armstrong T, Mackey M, Gilbert M, Krauze A, Camphausen K. Abstract 1433: A mobile app for health related quality of life and symptom assessment in patients with primary brain tumors in an outpatient oncology clinic Cancer Research. 76: 1433-1433. DOI: 10.1158/1538-7445.Am2016-1433 |
0.426 |
|
| 2016 |
Rowe L, Butman J, Mackey M, Shih J, Hawes M, Cooley Zgela T, Ning H, Smart D, Gilbert M, Camphausen K, Krauze A. RTHP-09. PROGRESSION AND PSEUDOPROGRESSION OF GLIOBLASTOMA MULTIFORME IN THE TEMOZOLOMIDE ERA Neuro-Oncology. 18: vi175-vi176. DOI: 10.1093/Neuonc/Now212.735 |
0.315 |
|
| 2016 |
Yust-Katz S, Cachia D, Kamiya-Matsuoka C, Theeler BJ, Olar A, Prado MP, Armstrong T, Gilbert M. RARE-03. EPENDYMOMAS ARISING OUTSIDE OF THE CENTRAL NERVOUS SYSTEM: A CASE SERIES Neuro-Oncology. 18: vi162-vi162. DOI: 10.1093/Neuonc/Now212.672 |
0.461 |
|
| 2016 |
Acquaye AA, Vera E, Gilbert MR, Armstrong TS. QLIF-17. THE IMPORTANCE OF THE CERN FOUNDATION ADULT EPENDYMOMA OUTCOMES PROJECT Neuro-Oncology. 18: vi159-vi159. DOI: 10.1093/Neuonc/Now212.662 |
0.458 |
|
| 2016 |
Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Coons SW, Bullard DE, Mehta MP, Gilbert MR, Brown PD, Stelzer KJ, McElroy JP, Fleming J, Chakraborty A, Becker AP, et al. MPTH-06. 1p/19q CO-DELETION STATUS PREDICTS SURVIVAL OUTCOMES IN NRG ONCOLOGY/RTOG 9802: A PHASE III TRIAL OF RT VS RT + PCV IN HIGH RISK LOW-GRADE GLIOMAS Neuro-Oncology. 18: vi106-vi106. DOI: 10.1093/Neuonc/Now212.444 |
0.316 |
|
| 2016 |
Vera E, Scheurer M, Zhou R, Gilbert MR, Bondy M, Sulman E, Yuan Y, Liu Y, Wendland M, Brachman D, Bearden J, McGovern SL, Wilson S, Judy K, Robins HI, et al. ACTR-21. OCCURRENCE AND IMPLICATIONS OF MYELOSUPPRESSION DURING CONCURRENT THERAPY ON RTOG 0825 Neuro-Oncology. 18: vi6-vi6. DOI: 10.1093/Neuonc/Now212.020 |
0.465 |
|
| 2016 |
Hwang E, Hardy K, Armstrong T, Acquaye A, Gioia A, Gilbert M, Mendoza T. QOS-12THE ASSOCIATION OF SOCIODEMOGRAPHIC AND MEDICAL FACTORS WITH CLINICAL OUTCOMES ASSESSMENTS (COAS) IN CHILDREN WITH EPENDYMOMA: RESULTS OF THE PEDIATRIC EPENDYMOMA OUTCOMES (PEO) PROJECT Neuro-Oncology. 18: iii147.4-iii147. DOI: 10.1093/Neuonc/Now081.12 |
0.501 |
|
| 2016 |
Theeler BJ, Gilbert MR. Investigating therapies in ependymoma Expert Opinion On Orphan Drugs. 4: 761-773. DOI: 10.1080/21678707.2016.1191347 |
0.351 |
|
| 2015 |
Theeler BJ, Gilbert MR. Advances in the treatment of newly diagnosed glioblastoma. Bmc Medicine. 13: 293. PMID 26646075 DOI: 10.1186/S12916-015-0536-8 |
0.386 |
|
| 2015 |
Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. The Lancet. Oncology. 16: e534-42. PMID 26545842 DOI: 10.1016/S1470-2045(15)00088-1 |
0.371 |
|
| 2015 |
Ziu M, Kalkanis SN, Gilbert M, Ryken TC, Olson JJ. The role of initial chemotherapy for the treatment of adults with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology. PMID 26530261 DOI: 10.1007/S11060-015-1931-X |
0.329 |
|
| 2015 |
Armstrong TS, Grant R, Gilbert MR, Lee JW, Norden AD. Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy. Neuro-Oncology. PMID 26527735 DOI: 10.1093/Neuonc/Nov269 |
0.527 |
|
| 2015 |
Robins HI, Zhang P, Gilbert MR, Chakravarti A, de Groot JF, Grimm SA, Wang F, Lieberman FS, Krauze A, Trotti AM, Mohile N, Kee AY, Colman H, Cavaliere R, Kesari S, et al. A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. Journal of Neuro-Oncology. PMID 26508094 DOI: 10.1007/S11060-015-1966-Z |
0.322 |
|
| 2015 |
Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Brown P, Butowski N, Chamberlain MC, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Holdhoff M, Junck L, Kaley T, et al. Central Nervous System Cancers, Version 1.2015. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 1191-202. PMID 26483059 DOI: 10.6004/Jnccn.2015.0148 |
0.363 |
|
| 2015 |
Raizer JJ, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Phuphanich S, Puduvalli VK, Loghin M, Paleologos N, Yuan Y, Liu D, Rademaker A, Yung WK, Vaillant B, ... ... Gilbert MR, et al. A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. Journal of Neuro-Oncology. PMID 26476729 DOI: 10.1007/S11060-015-1958-Z |
0.43 |
|
| 2015 |
Cachia D, Kamiya-Matsuoka C, Mandel JJ, Olar A, Cykowski MD, Armstrong TS, Fuller GN, Gilbert MR, De Groot JF. Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. Journal of Neuro-Oncology. PMID 26354773 DOI: 10.1007/S11060-015-1930-Y |
0.58 |
|
| 2015 |
Ladha H, Pawar T, Gilbert MR, Mandel J, O-Brien B, Conrad C, Fields M, Hanna T, Loch C, Armstrong TS. Wound healing complications in brain tumor patients on Bevacizumab. Journal of Neuro-Oncology. PMID 26298437 DOI: 10.1007/S11060-015-1868-0 |
0.492 |
|
| 2015 |
Armstrong TS, Vera-Bolanos E, Acquaye AA, Gilbert MR, Ladha H, Mendoza T. The symptom burden of primary brain tumors: evidence for a core set of tumor and treatment-related symptoms. Neuro-Oncology. PMID 26289592 DOI: 10.1093/Neuonc/Nov166 |
0.588 |
|
| 2015 |
Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, ... ... Gilbert MR, et al. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro-Oncology. 17: 1188-98. PMID 26250565 DOI: 10.1093/Neuonc/Nov095 |
0.3 |
|
| 2015 |
Acquaye AA, Lin L, Vera-Bolanos E, Gilbert MR, Armstrong TS. Hope and mood changes throughout the primary brain tumor illness trajectory. Neuro-Oncology. PMID 26109686 DOI: 10.1093/Neuonc/Nov101 |
0.58 |
|
| 2015 |
Subbiah IM, Lei X, Weinberg JS, Sulman EP, Chavez-MacGregor M, Tripathy D, Gupta R, Varma A, Chouhan J, Guevarra RP, Valero V, Gilbert MR, Gonzalez-Angulo AM. Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 2239-45. PMID 25987700 DOI: 10.1200/Jco.2014.58.8517 |
0.309 |
|
| 2015 |
Yust-Katz S, Mandel JJ, Wu J, Yuan Y, Webre C, Pawar TA, Lhadha HS, Gilbert MR, Armstrong TS. Venous thromboembolism (VTE) and glioblastoma. Journal of Neuro-Oncology. 124: 87-94. PMID 25985958 DOI: 10.1200/Jco.2014.32.15_Suppl.2033 |
0.566 |
|
| 2015 |
Pajtler KW, Witt H, Sill M, Jones DT, Hovestadt V, Kratochwil F, Wani K, Tatevossian R, Punchihewa C, Johann P, Reimand J, Warnatz HJ, Ryzhova M, Mack S, Ramaswamy V, ... ... Gilbert M, et al. Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell. 27: 728-43. PMID 25965575 DOI: 10.1016/J.Ccell.2015.04.002 |
0.552 |
|
| 2015 |
Xu H, Rahimpour S, Nesvick CL, Zhang X, Ma J, Zhang M, Zhang G, Wang L, Yang C, Hong CS, Germanwala AV, Elder JB, Ray-Chaudhury A, Yao Y, Gilbert MR, et al. Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy. Oncotarget. 6: 11882-93. PMID 25957416 DOI: 10.18632/Oncotarget.3592 |
0.379 |
|
| 2015 |
Liu Y, Zhou R, Sulman EP, Scheurer ME, Boehling N, Armstrong GN, Tsavachidis S, Liang FW, Etzel CJ, Conrad CA, Gilbert MR, Armstrong TS, Bondy ML, Wefel JS. Genetic Modulation of Neurocognitive Function in Glioma Patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3340-6. PMID 25904748 DOI: 10.1158/1078-0432.Ccr-15-0168 |
0.531 |
|
| 2015 |
Armstrong TS, Ying Y, Wu J, Acquaye AA, Vera-Bolanos E, Gilbert MR, Brown PD, Vardy J, Chung C. The relationship between corticosteroids and symptoms in patients with primary brain tumors: utility of the Dexamethasone Symptom Questionnaire-Chronic. Neuro-Oncology. 17: 1114-20. PMID 25862766 DOI: 10.1093/Neuonc/Nov054 |
0.562 |
|
| 2015 |
DeWire M, Fouladi M, Turner DC, Wetmore C, Hawkins C, Jacobs C, Yuan Y, Liu D, Goldman S, Fisher P, Rytting M, Bouffet E, Khakoo Y, Hwang EI, Foreman N, ... ... Gilbert MR, et al. An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN). Journal of Neuro-Oncology. 123: 85-91. PMID 25859842 DOI: 10.1007/S11060-015-1764-7 |
0.354 |
|
| 2015 |
Lin L, Chien LC, Acquaye AA, Vera-Bolanos E, Gilbert MR, Armstrong TS. Significant predictors of patients' uncertainty in primary brain tumors. Journal of Neuro-Oncology. 122: 507-15. PMID 25805495 DOI: 10.1007/S11060-015-1756-7 |
0.579 |
|
| 2015 |
Kamiya-Matsuoka C, Gilbert MR. Treating recurrent glioblastoma: an update. Cns Oncology. 4: 91-104. PMID 25768333 DOI: 10.2217/Cns.14.55 |
0.386 |
|
| 2015 |
Lassman AB, Pugh SL, Gilbert MR, Aldape KD, Geinoz S, Beumer JH, Christner SM, Komaki R, DeAngelis LM, Gaur R, Youssef E, Wagner H, Won M, Mehta MP. Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). Neuro-Oncology. 17: 992-8. PMID 25758746 DOI: 10.1093/Neuonc/Nov011 |
0.318 |
|
| 2015 |
Olar A, Wani KM, Alfaro-Munoz KD, Heathcock LE, van Thuijl HF, Gilbert MR, Armstrong TS, Sulman EP, Cahill DP, Vera-Bolanos E, Yuan Y, Reijneveld JC, Ylstra B, Wesseling P, Aldape KD. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathologica. 129: 585-96. PMID 25701198 DOI: 10.1007/S00401-015-1398-Z |
0.544 |
|
| 2015 |
Wang M, Dignam JJ, Won M, Curran W, Mehta M, Gilbert MR. Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525. Neuro-Oncology. 17: 999-1006. PMID 25688120 DOI: 10.1093/Neuonc/Nov009 |
0.321 |
|
| 2015 |
Ellingson BM, Kim E, Woodworth DC, Marques H, Boxerman JL, Safriel Y, McKinstry RC, Bokstein F, Jain R, Chi TL, Sorensen AG, Gilbert MR, Barboriak DP. Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma. International Journal of Oncology. 46: 1883-92. PMID 25672376 DOI: 10.3892/Ijo.2015.2891 |
0.343 |
|
| 2015 |
Weathers SP, Gilbert MR. Current challenges in designing GBM trials for immunotherapy. Journal of Neuro-Oncology. 123: 331-7. PMID 25577401 DOI: 10.1007/S11060-015-1716-2 |
0.36 |
|
| 2015 |
Cachia D, Wani K, Penas-Prado M, Olar A, McCutcheon IE, Benjamin RS, Armstrong TS, Gilbert MR, Aldape KD. C11orf95-RELA fusion present in a primary supratentorial ependymoma and recurrent sarcoma. Brain Tumor Pathology. 32: 105-11. PMID 25388523 DOI: 10.1007/S10014-014-0205-1 |
0.54 |
|
| 2015 |
Walbert T, Mendoza TR, Vera-Bolaños E, Acquaye A, Gilbert MR, Armstrong TS. Symptoms and socio-economic impact of ependymoma on adult patients: results of the Adult Ependymoma Outcomes Project 2. Journal of Neuro-Oncology. 121: 341-8. PMID 25359395 DOI: 10.1007/S11060-014-1638-4 |
0.568 |
|
| 2015 |
Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, Colman H, Dhall G, Lieberman FS, Metellus P, Mikkelsen T, Omuro A, Partap S, Prados M, Robins HI, ... ... Gilbert MR, et al. Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro-Oncology. 17: 440-7. PMID 25121770 DOI: 10.1093/Neuonc/Nou162 |
0.579 |
|
| 2015 |
Raizer JJ, Grimm SA, Penas-Prado M, Tremont-Lukats I, Yung WKA, Avgeropoulos NG, Walbert T, Loghin ME, Gilbert MR. A phase I trial everolimus and sorafenib in patients with recurrent high-grade gliomas: Brain Tumor Treatment Collaborative trial 09-01. Journal of Clinical Oncology. 33: 2061-2061. DOI: 10.1200/Jco.2015.33.15_Suppl.2061 |
0.394 |
|
| 2015 |
Penas-Prado M, Hess KR, Levin VA, De Groot JF, Colman H, Groves MD, Conrad CA, Loghin ME, Hunter K, Gilbert MR, Yung WKA, Puduvalli VK. Phase I study of vorinostat combined with isotretinoin and temozolomide in adults with recurrent malignant gliomas. Journal of Clinical Oncology. 33: 2039-2039. DOI: 10.1200/Jco.2015.33.15_Suppl.2039 |
0.348 |
|
| 2015 |
Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Groves MD, Raizer JJ, Giglio P, Colman H, Peereboom DM, Walbert T, Avgeropoulos NG, Iwamoto FM, Chamberlain MC, Paleologos N, Fink KL, ... ... Gilbert MR, et al. Brain Tumor Trials Collaborative Bayesian Adaptive Randomized Phase II trial of bevacizumab plus vorinostat versus bevacizumab alone in adults with recurrent glioblastoma (BTTC-1102). Journal of Clinical Oncology. 33: 2012-2012. DOI: 10.1200/Jco.2015.33.15_Suppl.2012 |
0.563 |
|
| 2015 |
Chang SM, Zhang P, Cairncross JG, Gilbert MR, Bahary J, Dolinskas C, Aldape KD, Chakravarti A, Schiff D, Jaeckle KA, Brown PD, Barger G, Werner-Wasik M, Shih HA, Brachman D, et al. Results of NRG oncology/RTOG 9813: A phase III randomized study of radiation therapy (RT) and temozolomide (TMZ) versus RT and nitrosourea (NU) therapy for anaplastic astrocytoma (AA). Journal of Clinical Oncology. 33: 2002-2002. DOI: 10.1200/Jco.2015.33.15_Suppl.2002 |
0.397 |
|
| 2015 |
Olar A, Wani K, Diefes K, Heathcock L, Thuijl Hv, Gilbert M, Armstrong T, Sulman E, Cahill D, Reijneveld J, Ylstra B, Wesseling P, Aldape K. Abstract 5270: IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas Cancer Research. 75: 5270-5270. DOI: 10.1158/1538-7445.Am2015-5270 |
0.36 |
|
| 2015 |
Blumenthal DT, Won M, Corn BW, Gilbert MR, Brown P, Bokstein F, Brachman DG, Werner-Wasik M, Hunter GK, Valeinis E, Kuehn EF, Hopkins K, Souhami L, Robins HI, Zhang P, et al. RTRB-03SHORT DELAY IN INITIATION OF RADIOTHERAPY WITH CONCURRENT CHEMOTHERAPY FOR GLIOBLASTOMA: A SECONDARY ANALYSIS OF NRG ONCOLOGY/RTOG 0525 AND 0825 Neuro-Oncology. 17: v195.3-v195. DOI: 10.1093/Neuonc/Nov231.03 |
0.382 |
|
| 2015 |
Bolanos EV, Acquaye A, Mendoza T, Gilbert M, Armstrong TS. QOL-25EVALUATION OF THE UTILITY OF THE EQ-5D AND MDASI-BT IN PRIMARY BRAIN TUMOR PATIENTS Neuro-Oncology. 17: v193.3-v193. DOI: 10.1093/Neuonc/Nov230.25 |
0.575 |
|
| 2015 |
Hwang E, Hardy K, Armstrong T, Acquaye A, Gilbert M, Mendoza T. QOL-12SELF- AND PROXY-REPORTED CLINICAL OUTCOMES ASSESSMENTS (COAS) IN A LARGE COHORT OF CHILDREN WITH EPENDYMOMA. Neuro-Oncology. 17: v190.3-v190. DOI: 10.1093/Neuonc/Nov230.12 |
0.489 |
|
| 2015 |
Acquaye A, Vera-Bolanos E, Armstrong T, Gilbert M. Qol-01The Adult Ependymoma Outcomes Project (Aeo) Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov230.01 |
0.456 |
|
| 2015 |
Leisy A, Armstrong T, Acquaye A, Vera-Bolanos E, Gilbert M, Cron S. PCSM-06COMPARISON OF THE SYMPTOM BURDEN IN ACTIVE TREATMENT VERSUS FOLLOW-UP FOR PRIMARY BRAIN TUMOR PATIENTS Neuro-Oncology. 17: v177.1-v177. DOI: 10.1093/Neuonc/Nov227.06 |
0.542 |
|
| 2015 |
Okada H, Weller M, Huang R, Finocchiaro G, Gilbert M, Wick W, Ellingson B, Hashimoto N, Pollack I, Brandes A, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope W, et al. NIMG-56IMMUNOTHERAPY RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (iRANO): A REPORT OF THE RANO WORKING GROUP Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov225.56 |
0.396 |
|
| 2015 |
Wefel J, Bradshaw M, Sullaway C, Gilbert M, Armstrong T. NCO-17A BRAIN-PLASTICITY BASED COMPUTERIZED INTERVENTION TO TREAT ATTENTION AND MEMORY PROBLEMS IN ADULT BRAIN TUMOR (BT) SURVIVORS Neuro-Oncology. 17: v149.4-v150. DOI: 10.1093/Neuonc/Nov223.17 |
0.521 |
|
| 2015 |
Zhou R, Scheurer M, Gilbert M, Bondy M, Sulman E, Yuan Y, Liu Y, Vera-Bolanos E, Wendland M, Brachman D, Bearden J, McGovern S, Wilson S, Judy K, Robins HI, et al. EPID-33RISK MODELING FOR VASCULAR TOXICITY IN PATIENTS WITH GLIOBLASTOMA (GBM) TREATED ON NRG ONCOLOGY/RTOG 0825 Neuro-Oncology. 17: v85.3-v85. DOI: 10.1093/Neuonc/Nov213.33 |
0.527 |
|
| 2015 |
Scheurer ME, Zhou R, Gilbert MR, Bondy ML, Sulman EP, Yuan Y, Liu Y, Vera-Bolanos E, Wendland MM, Brachman DG, Stieber VW, Komaki RR, Flickinger JC, Kenyon LC, Robins HI, et al. EPID-25GERMLINE POLYMORPHISMS IN MGMT INCREASE ABILITY TO MODEL TEMOZOLOMIDE (TMZ)-RELATED MYELOTOXICITY RISK IN PATIENTS WITH GLIOBLASTOMA (GBM) TREATED ON NRG ONCOLOGY/RTOG 0825 Neuro-Oncology. 17: v83.3-v83. DOI: 10.1093/Neuonc/Nov213.25 |
0.514 |
|
| 2015 |
Wu J, Puduvalli VK, Yuan Y, Armstrong T, Walker B, Upshaw C, Giglio P, Colman H, Groves MD, Raizer J, Walbert T, Tran D, Avgeropoulos N, Iwamoto F, Peereboom D, ... ... Gilbert MR, et al. ATCT-34BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB PLUS VORINOSTAT VERSUS BEVACIZUMAB ALONE IN ADULTS WITH RECURRENT GLIOBLASTOMA Neuro-Oncology. 17: v9.2-v9. DOI: 10.1093/Neuonc/Nov206.34 |
0.599 |
|
| 2015 |
Shi W, Bryan M, Gilbert M, Mehta M, Blumenthal D, Brown P, Valeinis E, Hopkins K, Souhami L, Andrews D, Tzahala T, Howard S, Youssef E, Lessard N, Dignam J, et al. ATCT-29INVESTIGATING THE EFFECT OF REIRRADIATION OR SYSTEMIC THERAPY IN PATIENTS WITH GBM AFTER TUMOR PROGRESSION: A SECONDARY ANALYSIS OF THE NRG ONCOLOGY/RTOG 0525 Neuro-Oncology. 17: v8.1-v8. DOI: 10.1093/Neuonc/Nov206.29 |
0.373 |
|
| 2015 |
Robins HI, Zhang P, Gilbert M, Chakravarti A, deGroot J, Grimm S, Wang F, Lieberman F, Krauze A, Sharma A, Mohile N, Kee A, Colman H, Cavaliere R, Kesari S, et al. Atct-27Nrg Oncology/Rtog 0929: A Randomized Phase I/Ii Study Of Abt-888In Combination With Temozolomide In Recurrent Temozolomide Resistant Glioblastoma Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov206.27 |
0.325 |
|
| 2015 |
Chang S, Zhang P, Cairncross JG, Gilbert MR, Bahary JP, Dolinskas C, Aldape KD, Bell E, Sciff D, Jaeckle K, Brown PD, Barger GR, Werner-Wasik M, Shih H, Brachman D, et al. ATCT-12RESULTS OF NRG ONCOLOGY/RTOG 9813- A PHASE III RANDOMIZED STUDY OF RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) VERSUS RT AND NITROSOUREA (NU) THERAPY FOR ANAPLASTIC ASTROCYTOMA (AA) Neuro-Oncology. 17: v3.4-v3. DOI: 10.1093/Neuonc/Nov206.12 |
0.408 |
|
| 2015 |
Buckner J, Shaw E, Pugh S, Gilbert M, Barger G, Coons S, Ricci P, Bullard D, Brown P, Stelzer K, Brachman D, Suh J, Schultz C, Bahary J, Fisher B, et al. ATCT-09IDH1 R132H MUTATIONS IN NRG ONCOLOGY/RTOG 9802: PHASE III STUDY OF RADIATION THERAPY (RT) ALONE VS RT PLUS PROCARBAZINE, CCNU, AND VINCRISTINE (PCV) IN PATIENTS WITH LOW GRADE GLIOMA (LGG) Neuro-Oncology. 17: v3.1-v3. DOI: 10.1093/Neuonc/Nov206.09 |
0.36 |
|
| 2015 |
Raizer J, Grimm S, Penas-Prado M, Tremont-Lukats I, Yung A, Avgeropoulos N, Walbert T, Loghin M, Gilbert M. Atnt-20A Phase I-Ii Trial Everolimus And Sorafenib In Patients With Recurrent High-Grade Gliomas: Brain Tumor Treatment Collaborative Trial 09-01 Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov205.20 |
0.364 |
|
| 2015 |
Happold C, Gorlia T, Chinot O, Gilbert M, Nabors B, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, Reardon D, Perry JR, Mehta M, Stupp R, Weller M. ATNT-10DOES VALPROIC ACID IMPROVE SURVIVAL IN GLIOBLASTOMA? A META-ANALYSIS OF RANDOMIZED TRIALS IN NEWLY DIAGNOSED GLIOBLASTOMA Neuro-Oncology. 17: v12.2-v12. DOI: 10.1093/Neuonc/Nov205.10 |
0.318 |
|
| 2015 |
Hall W, Pugh S, Gilbert M, Wefel J, Armstrong T, Wendland M, Brachman D, Roof K, Brown P, Crocker I, Robins H, Lee R, Chao S, Kim L, Srkalovic G, et al. Bevacizumab Use in Patients With Subtotal Resection of Newly Diagnosed Glioblastoma (GBM): A Secondary Analysis of NRG Oncology/RTOG 0825 International Journal of Radiation Oncology*Biology*Physics. 93: S110. DOI: 10.1016/J.Ijrobp.2015.07.2257 |
0.548 |
|
| 2014 |
Kamiya-Matsuoka C, Cachia D, Olar A, Armstrong TS, Gilbert MR. Primary brain tumors and posterior reversible encephalopathy syndrome. Neuro-Oncology Practice. 1: 184-190. PMID 26034631 DOI: 10.1093/Nop/Npu024 |
0.579 |
|
| 2014 |
Cahill JE, Lin L, LoBiondo-Wood G, Armstrong TS, Acquaye AA, Vera-Bolanos E, Gilbert MR, Padhye NS. Personal health records, symptoms, uncertainty, and mood in brain tumor patients. Neuro-Oncology Practice. 1: 64-70. PMID 26034618 DOI: 10.1093/Nop/Npu005 |
0.564 |
|
| 2014 |
Armstrong TS, Vera-Bolanos E, Acquaye A, Gilbert MR, Mendoza TR. Impact of recall period on primary brain tumor patient's self-report of symptoms. Neuro-Oncology Practice. 1: 55-63. PMID 26034617 DOI: 10.1093/Nop/Npu006 |
0.564 |
|
| 2014 |
Gilbert MR, Armstrong TS, Pope WB, van den Bent MJ, Wen PY. Facing the future of brain tumor clinical research. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5591-600. PMID 25398842 DOI: 10.1158/1078-0432.Ccr-14-0835 |
0.573 |
|
| 2014 |
Nabors LB, Portnow J, Ammirati M, Brem H, Brown P, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Hesser D, Holdhoff M, Junck L, et al. Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network : Jnccn. 12: 1517-23. PMID 25361798 DOI: 10.6004/Jnccn.2014.0151 |
0.369 |
|
| 2014 |
Armstrong TS, Gilbert MR. Patient reported endpoints for measuring clinical benefit in (high grade glioma) primary brain tumor patients. Current Treatment Options in Oncology. 15: 519-28. PMID 25173554 DOI: 10.1007/S11864-014-0302-8 |
0.622 |
|
| 2014 |
Mandel JJ, Yust-Katz S, Cachia D, Wu J, Liu D, de Groot JF, Yung AW, Gilbert MR. Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution. Journal of Neuro-Oncology. 120: 597-605. PMID 25168214 DOI: 10.1007/S11060-014-1592-1 |
0.415 |
|
| 2014 |
Weathers SP, Gilbert MR. Advances in treating glioblastoma. F1000prime Reports. 6: 46. PMID 24991423 DOI: 10.12703/P6-46 |
0.349 |
|
| 2014 |
Anderson MD, Gilbert MR. Clinical discussion of the management of anaplastic oligodendroglioma/oligoastrocytoma (both codeleted and nondeleted). Journal of the National Comprehensive Cancer Network : Jnccn. 12: 665-72. PMID 24812135 DOI: 10.6004/Jnccn.2014.0070 |
0.423 |
|
| 2014 |
Gabrusiewicz K, Liu D, Cortes-Santiago N, Hossain MB, Conrad CA, Aldape KD, Fuller GN, Marini FC, Alonso MM, Idoate MA, Gilbert MR, Fueyo J, Gomez-Manzano C. Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. Oncotarget. 5: 2208-20. PMID 24809734 DOI: 10.18632/Oncotarget.1893 |
0.366 |
|
| 2014 |
Hamza MA, Mandel JJ, Conrad CA, Gilbert MR, Yung WK, Puduvalli VK, DeGroot JF. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. Journal of Neuro-Oncology. 119: 135-40. PMID 24803001 DOI: 10.1200/Jco.2013.31.15_Suppl.2042 |
0.378 |
|
| 2014 |
Kim BY, Jiang W, Beiko J, Prabhu SS, DeMonte F, Gilbert MR, Sawaya R, Aldape KD, Cahill DP, McCutcheon IE. Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing. Journal of Neuro-Oncology. 118: 405-12. PMID 24777756 DOI: 10.1007/S11060-014-1451-0 |
0.386 |
|
| 2014 |
Gilbert MR, Dignam J, Pugh S, Armstrong TS, Wefel JS, Aldape K, Stupp R, Hegi M, Won M, Curran WJ, Mehta MP. Reply to M.C. Chamberlain. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1634-5. PMID 24752060 DOI: 10.1200/Jco.2013.54.9717 |
0.575 |
|
| 2014 |
Yust-Katz S, de Groot JF, Liu D, Wu J, Yuan Y, Anderson MD, Conrad CA, Milbourne A, Gilbert MR, Armstrong TS. Pregnancy and glial brain tumors. Neuro-Oncology. 16: 1289-94. PMID 24615863 DOI: 10.1093/Neuonc/Nou019 |
0.536 |
|
| 2014 |
Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The New England Journal of Medicine. 370: 699-708. PMID 24552317 DOI: 10.1056/Nejmoa1308573 |
0.563 |
|
| 2014 |
Hamza MA, Gilbert M. Targeted therapy in gliomas. Current Oncology Reports. 16: 379. PMID 24510741 DOI: 10.1007/S11912-014-0379-Z |
0.354 |
|
| 2014 |
Cahill JE, Gilbert MR, Armstrong TS. Personal health records as portal to the electronic medical record. Journal of Neuro-Oncology. 117: 1-6. PMID 24477621 DOI: 10.1007/S11060-013-1333-X |
0.532 |
|
| 2014 |
Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, et al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro-Oncology. 16: 567-78. PMID 24470557 DOI: 10.1093/Neuonc/Not247 |
0.387 |
|
| 2014 |
Prabhu RS, Won M, Shaw EG, Hu C, Brachman DG, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta MP. Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 535-41. PMID 24419119 DOI: 10.1200/Jco.2013.53.1830 |
0.371 |
|
| 2014 |
Patel JD, Krilov L, Adams S, Aghajanian C, Basch E, Brose MS, Carroll WL, de Lima M, Gilbert MR, Kris MG, Marshall JL, Masters GA, O'Day SJ, Polite B, Schwartz GK, et al. Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 129-60. PMID 24327669 DOI: 10.1200/Jco.2013.53.7076 |
0.306 |
|
| 2014 |
Barney CL, Brown AP, Grosshans DR, McAleer MF, de Groot JF, Puduvalli V, Tucker SL, Crawford CN, Gilbert MR, Brown PD, Mahajan A. Technique, outcomes, and acute toxicities in adults treated with proton beam craniospinal irradiation. Neuro-Oncology. 16: 303-9. PMID 24311638 DOI: 10.1093/Neuonc/Not155 |
0.355 |
|
| 2014 |
Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, Shonka N, Gilbert MR, Sawaya R, Prabhu SS, Weinberg J, Lang FF, Aldape KD, Sulman EP, Rao G, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro-Oncology. 16: 81-91. PMID 24305719 DOI: 10.1093/Neuonc/Not159 |
0.351 |
|
| 2014 |
Wen PY, Yung WKA, Mellinghoff IK, Ramkissoon S, Alexander BM, Rinne ML, Colman H, Omuro AMP, DeAngelis LM, Gilbert MR, De Groot JF, Cloughesy TF, Chi AS, Lee EQ, Nayak L, et al. Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastoma. Journal of Clinical Oncology. 32: 2019-2019. DOI: 10.1200/Jco.2014.32.15_Suppl.2019 |
0.368 |
|
| 2014 |
Buckner JC, Pugh SL, Shaw EG, Gilbert MR, Barger G, Coons S, Ricci P, Bullard D, Brown PD, Stelzer K, Brachman D, Suh JH, Schultz CJ, Bahary J, Fisher BJ, et al. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. Journal of Clinical Oncology. 32: 2000-2000. DOI: 10.1200/Jco.2014.32.15_Suppl.2000 |
0.359 |
|
| 2014 |
Yust-Katz S, Mandel J, Ying Y, Wu J, Courtney C, Ladha H, Pawar T, Gilbert M, Armstrong T. SP-05 * VENOUS THROMBOEMBOLISM AND GLIOBLASTOMA Neuro-Oncology. 16: v212-v212. DOI: 10.1093/Neuonc/Nou276.5 |
0.562 |
|
| 2014 |
Lin L, Chien L, Acquaye A, Vera-Bolanos E, Gilbert M, Armstrong T. QL-19A FOLLOW-UP OF A SURVEY OF ILLNESS-RELATED UNCERTAINTY AND MOOD IN PATIENTS WITH PRIMARY BRAIN TUMORS (PBTs) Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou269.18 |
0.401 |
|
| 2014 |
Hall WA, Pugh SL, Wefel JS, Armstrong TS, Gilbert MR, Brachman DG, Werner-Wasik M, Wendland M, Brown PD, Chao ST, Roof K, Robins HI, Curran WJ, Mehta M. Nc-05Association Of Neurocognitive And Patient Reported Outcomes With The Presence Of Residual Disease Following Surgical Resection In Glioblastoma (Gbm) Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou263.5 |
0.376 |
|
| 2014 |
Liu Y, Zhou R, Sulman E, Scheurer M, Boehling N, Gilbert M, Armstrong T, Bondy M, Wefel J. ED-17 * GENETIC MODULATION OF NEUROCOGNITIVE FUNCTION AND OUTCOMES IN GLIOMA PATIENTS Neuro-Oncology. 16: v69-v69. DOI: 10.1093/Neuonc/Nou253.17 |
0.485 |
|
| 2014 |
Kamiya-Matsuoka C, Cachia D, Armstrong T, Gilbert M. CN-09 * POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME AND PRIMARY BRAIN TUMORS Neuro-Oncology. 16: v47-v48. DOI: 10.1093/Neuonc/Nou243.9 |
0.592 |
|
| 2014 |
Zhou R, Scheurer M, Vera-Bolanos E, Gilbert M, Bondy M, Sulman E, Hilsenbeck S, Wendland M, Brachman D, Roof K, Komaki R, Deutsch M, Andrews D, Anderson B, Lee RJ, et al. CN-21 * RISK MODELING FOR TEMOZOLOMIDE (TMZ)-MYELOTOXICITY IN PATIENTS WITH GLIOBLASTOMA TREATED ON RTOG 0825 Neuro-Oncology. 16: v50-v50. DOI: 10.1093/Neuonc/Nou243.21 |
0.512 |
|
| 2014 |
Pawar T, Ladha H, Mandel J, Gilbert M, O'Brien B, Hamza M, Armstrong T. CN-15 * ADVERSE EFFECTS OF BEVACIZUMAB IN BRAIN TUMOR PATIENTS Neuro-Oncology. 16: v49-v49. DOI: 10.1093/Neuonc/Nou243.15 |
0.56 |
|
| 2014 |
Wani K, Armstrong TS, Jones DT, Vera-Bolanos E, Witt H, Capper D, Pfister SM, Gilbertson RJ, Gilbert MR, Aldape K. BI-30 * CHARACTERIZATION OF L1CAM AS A CLINICAL MARKER FOR THE C11orf95-RELA FUSION IN SUPRATENTORIAL EPENDYMOMAS Neuro-Oncology. 16: v30-v30. DOI: 10.1093/Neuonc/Nou239.30 |
0.515 |
|
| 2014 |
Bell EH, Pugh S, Gilbert M, Mehta M, Klimowicz A, Magliocco A, Bredel M, Robe P, Grosu A, Stupp R, Curran W, Corn B, Brown P, Glass J, Souhami L, et al. BI-12 * RTOG 0525 RECURSIVE PARTITIONING ANALYSIS BASED ON CLINICAL AND PROTEIN BIOMARKER PARAMETERS Neuro-Oncology. 16: v25-v25. DOI: 10.1093/Neuonc/Nou239.12 |
0.334 |
|
| 2014 |
Ladha H, Pawar T, Gilbert M, O'Brien B, Conrad C, Fields M, Hanna T, Loch C, Armstrong T. AI-18 * WOUND HEALING COMPLICATIONS IN A SERIES OF BRAIN TUMOR PATIENTS ON BEVACIZUMAB Neuro-Oncology. 16: v5-v5. DOI: 10.1093/Neuonc/Nou238.18 |
0.497 |
|
| 2014 |
Armstrong TS, Vera-Bolanos E, Gilbert M, Yuan Y, Wani K, Wu J, Omuro A, Lieberman F, Robins HI, Gerstner E, Wu J, Wen P, Mikkelsen T, Aldape K, Mendoza T. At-07A Phase Ii Study Of Lapatinib And Dose-Dense Temozolomide (Tmz) For Adults With Recurrent Ependymoma: Patient Reported Outcomes (Pro) From A Cern Clinical Trial. Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.7 |
0.412 |
|
| 2014 |
Gilbert M, Yuan Y, Wani K, Wu J, Omuro A, Lieberman F, Robins HI, Gerstner E, Wu J, Wen P, Mikkelsen T, Armstrong T, Aldape K. AT-23 * A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: A CERN CLINICAL TRIAL Neuro-Oncology. 16: v13-v13. DOI: 10.1093/Neuonc/Nou237.23 |
0.601 |
|
| 2014 |
Buckner J, Shaw E, Pugh S, Gilbert M, Barger G, Coons S, Ricci P, Bullard D, Brown P, Stelzer K, Brachman D, Suh J, Schultz C, Bahary J, Fisher B, et al. AT-13 * R9802: PHASE III STUDY OF RADIATION THERAPY (RT) WITH OR WITHOUT PROCARBAZINE, CCNU, AND VINCRISTINE (PCV) IN LOW-GRADE QLIOMA: RESULTS BY HISTOLOGIC TYPE Neuro-Oncology. 16: v11-v11. DOI: 10.1093/Neuonc/Nou237.13 |
0.351 |
|
| 2014 |
Gomez-Manzano C, Gabrusiewicz K, Cortes-Santiago N, Hossain MB, Conrad C, Fuller G, Aldape K, Lang F, Gilbert M, Yung WKA, Fueyo J. Presence Of A Distinctive Myeloid Population Is Associated With The Invasive Tumor Phenotype Observed After Anti-Angiogenesis Therapies. Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou206.53 |
0.356 |
|
| 2014 |
Mehta M, Won M, Shaw E, Buckner J, Gilbert M, Barger G, Coons S, Ricci P, Bullard D, Brown P, Stelzer K, Brachman D, Suh J, Schultz C, Bahary J, et al. Mature Survival Data from RTOG 9802: A Phase III Study of Radiation Therapy (RT) With or Without Procarbazine, CCNU, and Vincristine (PCV) for Adult Patients with High-Risk Low-Grade Glioma (LGG) International Journal of Radiation Oncology*Biology*Physics. 90: S37-S38. DOI: 10.1016/J.Ijrobp.2014.05.153 |
0.342 |
|
| 2013 |
Doucette T, Rao G, Rao A, Shen L, Aldape K, Wei J, Dziurzynski K, Gilbert M, Heimberger AB. Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. Cancer Immunology Research. 1: 112-22. PMID 24409449 DOI: 10.1158/2326-6066.Cir-13-0028 |
0.339 |
|
| 2013 |
Armstrong TS, Wefel JS, Wang M, Gilbert MR, Won M, Bottomley A, Mendoza TR, Coens C, Werner-Wasik M, Brachman DG, Choucair AK, Mehta M. Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 4076-84. PMID 24101048 DOI: 10.1200/Jco.2013.49.6067 |
0.571 |
|
| 2013 |
Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 4085-91. PMID 24101040 DOI: 10.1200/Jco.2013.49.6968 |
0.574 |
|
| 2013 |
Ghia AJ, Mahajan A, Allen PK, Armstrong TS, Lang FF, Gilbert MR, Brown PD. Supratentorial gross-totally resected non-anaplastic ependymoma: population based patterns of care and outcomes analysis. Journal of Neuro-Oncology. 115: 513-20. PMID 24085643 DOI: 10.1007/S11060-013-1254-8 |
0.551 |
|
| 2013 |
Nabors LB, Ammirati M, Bierman PJ, Brem H, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Holdhoff M, Junck L, Lawson R, Loeffler JS, et al. Central nervous system cancers. Journal of the National Comprehensive Cancer Network : Jnccn. 11: 1114-51. PMID 24029126 DOI: 10.6004/Jnccn.2013.0132 |
0.438 |
|
| 2013 |
Anderson MD, Gilbert MR. Treatment recommendations for anaplastic oligodendrogliomas that are codeleted. Oncology (Williston Park, N.Y.). 27: 315-20, 322. PMID 23781695 DOI: 10.1159/000224744 |
0.365 |
|
| 2013 |
Acquaye AA, Vera-Bolanos E, Armstrong TS, Gilbert MR, Lin L. Mood disturbance in glioma patients. Journal of Neuro-Oncology. 113: 505-12. PMID 23677748 DOI: 10.1007/s11060-013-1143-1 |
0.522 |
|
| 2013 |
Lin L, Chiang HH, Acquaye AA, Vera-Bolanos E, Gilbert MR, Armstrong TS. Uncertainty, mood states, and symptom distress in patients with primary brain tumors: analysis of a conceptual model using structural equation modeling. Cancer. 119: 2796-806. PMID 23661311 DOI: 10.1002/cncr.28121 |
0.521 |
|
| 2013 |
Ratai EM, Zhang Z, Snyder BS, Boxerman JL, Safriel Y, McKinstry RC, Bokstein F, Gilbert MR, Sorensen AG, Barboriak DP. Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677. Neuro-Oncology. 15: 936-44. PMID 23645534 DOI: 10.1093/Neuonc/Not044 |
0.399 |
|
| 2013 |
Yust-Katz S, Liu D, Yuan Y, Liu V, Kang S, Groves M, Puduvalli V, Levin V, Conrad C, Colman H, Hsu S, Yung WK, Gilbert MR. Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma. Cancer. 119: 2747-53. PMID 23633392 DOI: 10.1002/Cncr.28031 |
0.356 |
|
| 2013 |
Shonka NA, Theeler B, Cahill D, Yung A, Smith L, Lei X, Gilbert MR. Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide. Journal of Neuro-Oncology. 113: 305-11. PMID 23526410 DOI: 10.1007/S11060-013-1116-4 |
0.364 |
|
| 2013 |
Raghunathan A, Wani K, Armstrong TS, Vera-Bolanos E, Fouladi M, Gilbertson R, Gajjar A, Goldman S, Lehman NL, Metellus P, Mikkelsen T, Necesito-Reyes MJ, Omuro A, Packer RJ, Partap S, ... ... Gilbert MR, et al. Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system. Brain Pathology (Zurich, Switzerland). 23: 584-94. PMID 23452038 DOI: 10.1111/Bpa.12050 |
0.546 |
|
| 2013 |
Brown AP, Barney CL, Grosshans DR, McAleer MF, de Groot JF, Puduvalli VK, Tucker SL, Crawford CN, Khan M, Khatua S, Gilbert MR, Brown PD, Mahajan A. Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma. International Journal of Radiation Oncology, Biology, Physics. 86: 277-84. PMID 23433794 DOI: 10.1016/J.Ijrobp.2013.01.014 |
0.306 |
|
| 2013 |
Walker GV, Gilbert MR, Prabhu SS, Brown PD, McAleer MF. Temozolomide use in adult patients with gliosarcoma: an evolving clinical practice. Journal of Neuro-Oncology. 112: 83-9. PMID 23266723 DOI: 10.1007/S11060-012-1029-7 |
0.388 |
|
| 2013 |
Gilbert MR. On the pathway to success: defining subtypes of gliomas for better treatment selection and refining the meaning of success. Current Oncology Reports. 15: 24-6. PMID 23180217 DOI: 10.1007/S11912-012-0282-4 |
0.404 |
|
| 2013 |
Gilbert MR. Minding the Ps and Qs: perseverance and quality studies lead to major advances in patients with anaplastic oligodendroglioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 299-300. PMID 23071223 DOI: 10.1200/Jco.2012.44.4513 |
0.432 |
|
| 2013 |
Nayak L, Abrey LE, Drappatz J, Gilbert MR, Reardon DA, Wen PY, Prados M, Deangelis LM, Omuro A. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leukemia & Lymphoma. 54: 58-61. PMID 22656234 DOI: 10.3109/10428194.2012.698736 |
0.353 |
|
| 2013 |
Penas-Prado M, Groves MD, Mammoser AG, Melguizo I, De Groot JF, Conrad CA, Tremont-Lukats I, Loghin ME, Puduvalli VK, Sulman EP, Hess KR, Aldape KD, Gilbert MR, Yung WKA. Phase I lead-in to a 2x2x2 factorial trial of dose-dense temozolomide, memantine, mefloquine, and metformin as postradiation adjuvant therapy of glioblastoma (GBM). Journal of Clinical Oncology. 31: TPS2106-TPS2106. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps2106 |
0.353 |
|
| 2013 |
Sulman EP, Won M, Blumenthal DT, Vogelbaum MA, Colman H, Jenkins RB, Chakravarti A, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Dignam J, Atkins JN, Brachman D, Werner-Wasik M, ... ... Gilbert MR, et al. Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM). Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.Lba2010 |
0.343 |
|
| 2013 |
Garciarena P, Anderson MD, Hamilton J, Schellingerhout D, Fuller GN, Sawaya R, Gilbert MR. Textiloma mimicking recurrent glioblastoma: A case report. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.E13044 |
0.333 |
|
| 2013 |
Raizer JJ, Giglio P, Hu JL, Groves MD, Merrell R, Conrad CA, Phuphanich S, Puduvalli VK, Loghin ME, Paleologos N, Yung WKA, Vaillant BD, Rudnick JD, Chamberlain MC, Vick N, ... ... Gilbert MR, et al. BTTC08-01: A phase II study of bevacizumab and erlotinib after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma (GBM) without MGMT promoter methylation. Journal of Clinical Oncology. 31: 2019-2019. DOI: 10.1200/Jco.2013.31.15_Suppl.2019 |
0.442 |
|
| 2013 |
Wen PY, Yung WKA, Mellinghoff IK, Lamborn K, Ramkissoon S, Cloughesy TF, Rinne M, Omuro AMP, DeAngelis LM, Gilbert MR, Chi AS, Batchelor T, Colman H, Chang SM, Massacesi C, et al. Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM). Journal of Clinical Oncology. 31: 2015-2015. DOI: 10.1200/Jco.2013.31.15_Suppl.2015 |
0.44 |
|
| 2013 |
Wefel JS, Pugh SL, Armstrong TS, Gilbert MR, Won M, Wendland MM, Brachman D, Komaki R, Crocker IR, Robins HI, Lee RJ, Mehta MP. Neurocognitive function (NCF) outcomes in patients with glioblastoma (GBM) enrolled in RTOG 0825. Journal of Clinical Oncology. 31: 2004-2004. DOI: 10.1200/Jco.2013.31.15_Suppl.2004 |
0.52 |
|
| 2013 |
Armstrong TS, Won M, Wefel JS, Gilbert MR, Pugh SL, Brachman D, Komaki R, Crocker IR, Robins HI, Lee RJ, Mehta MP, Wendland MM. Comparative impact of treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825. Journal of Clinical Oncology. 31: 2003-2003. DOI: 10.1200/Jco.2013.31.15_Suppl.2003 |
0.566 |
|
| 2013 |
Gilbert MR, Dignam J, Won M, Blumenthal DT, Vogelbaum MA, Aldape KD, Colman H, Chakravarti A, Jeraj R, Armstrong TS, Wefel JS, Brown PD, Jaeckle KA, Schiff D, Atkins JN, et al. RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). Journal of Clinical Oncology. 31: 1-1. DOI: 10.1200/Jco.2013.31.15_Suppl.1 |
0.373 |
|
| 2013 |
Doucette T, Rao G, Aldape K, Wei J, Dziurzynski K, Rao A, Shen L, Gilbert MR, Heimberger AB. Abstract B82: Immune signatures of glioblastoma subtypes: Extrapolation from the Cancer Genome Atlas. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-B82 |
0.336 |
|
| 2013 |
Ramanathan RK, Hamburg SI, Borad MJ, Seetharam M, Kundranda MN, Lee P, Fredlund P, Gilbert M, Mast C, Semple SC, Judge AD, Crowell B, Vocila L, MacLachlan I, Northfelt DW. Abstract LB-289: A phase I dose escalation study of TKM-080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-289 |
0.383 |
|
| 2013 |
Cahill DP, George A, Gilbert MR, Chakravarti A, Stupp R, Hegi M, Brown P, Jaeckle KA, Corn B, Sulman EP, Souhami L, Werner-Wasik M, Anderson BM, Mehta M, Aldape KD. Abstract A110: EGFRvIII expression is associated with shorter progression-free and overall survival in glioblastoma patients treated with standard-of-care temozolomide and radiation: A report from the RTOG-0525 trial. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A110 |
0.382 |
|
| 2012 |
Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WK, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, ... ... Gilbert MR, et al. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro-Oncology. 14: 1511-8. PMID 23099651 DOI: 10.1093/Neuonc/Nos264 |
0.359 |
|
| 2012 |
Armstrong TS, Gilbert MR. Practical strategies for management of fatigue and sleep disorders in people with brain tumors. Neuro-Oncology. 14: iv65-72. PMID 23095832 DOI: 10.1093/Neuonc/Nos210 |
0.528 |
|
| 2012 |
Lin L, Acquaye AA, Vera-Bolanos E, Cahill JE, Gilbert MR, Armstrong TS. Validation of the Mishel's uncertainty in illness scale-brain tumor form (MUIS-BT). Journal of Neuro-Oncology. 110: 293-300. PMID 22965831 DOI: 10.1007/S11060-012-0971-8 |
0.578 |
|
| 2012 |
Shaw EG, Wang M, Coons SW, Brachman DG, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta MP. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3065-70. PMID 22851558 DOI: 10.1200/Jco.2011.35.8598 |
0.351 |
|
| 2012 |
Amirian ES, Armstrong TS, Aldape KD, Gilbert MR, Scheurer ME. Predictors of survival among pediatric and adult ependymoma cases: a study using Surveillance, Epidemiology, and End Results data from 1973 to 2007. Neuroepidemiology. 39: 116-24. PMID 22846789 DOI: 10.1159/000339320 |
0.564 |
|
| 2012 |
Galanis E, Wu W, Cloughesy T, Lamborn K, Mann B, Wen PY, Reardon DA, Wick W, Macdonald D, Armstrong TS, Weller M, Vogelbaum M, Colman H, Sargent DJ, van den Bent MJ, ... Gilbert M, et al. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. The Lancet. Oncology. 13: e196-204. PMID 22554547 DOI: 10.1016/S1470-2045(11)70406-5 |
0.517 |
|
| 2012 |
Armstrong TS, Wefel JS, Gning I, Acquaye A, Vera-Bolanos E, Gilbert MR, Cleeland CS, Mendoza T. Congruence of primary brain tumor patient and caregiver symptom report. Cancer. 118: 5026-37. PMID 22415423 DOI: 10.1002/Cncr.27483 |
0.577 |
|
| 2012 |
Wani K, Armstrong TS, Vera-Bolanos E, Raghunathan A, Ellison D, Gilbertson R, Vaillant B, Goldman S, Packer RJ, Fouladi M, Pollack I, Mikkelsen T, Prados M, Omuro A, Soffietti R, ... ... Gilbert MR, et al. A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathologica. 123: 727-38. PMID 22322993 DOI: 10.1007/S00401-012-0941-4 |
0.544 |
|
| 2012 |
Armstrong TS, Wen PY, Gilbert MR, Schiff D. Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. Neuro-Oncology. 14: 1203-14. PMID 22307472 DOI: 10.1093/Neuonc/Nor223 |
0.548 |
|
| 2012 |
Penas-Prado M, Armstrong TS, Gilbert MR. Glioblastoma. Handbook of Clinical Neurology. 105: 485-506. PMID 22230514 DOI: 10.1016/B978-0-444-53502-3.00004-5 |
0.536 |
|
| 2012 |
Goldlust SA, Cavaliere R, Newton HB, Hsu M, Deangelis LM, Batchelor TT, Gilbert MR, Lassman AB. Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors. Journal of Neuro-Oncology. 107: 407-11. PMID 22203237 DOI: 10.1007/S11060-011-0768-1 |
0.339 |
|
| 2012 |
Giglio P, Dhamne M, Hess KR, Gilbert MR, Groves MD, Levin VA, Kang SL, Ictech SE, Liu V, Colman H, Conrad CA, Loghin M, de Groot J, Yung WK, Puduvalli VK. Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer. 118: 3599-606. PMID 22086614 DOI: 10.1002/Cncr.26663 |
0.383 |
|
| 2012 |
Ellezam B, Theeler BJ, Luthra R, Adesina AM, Aldape KD, Gilbert MR. Recurrent PIK3CA mutations in rosette-forming glioneuronal tumor. Acta Neuropathologica. 123: 285-7. PMID 21997360 DOI: 10.1007/S00401-011-0886-Z |
0.393 |
|
| 2012 |
Amirian ES, Armstrong TS, Gilbert MR, Scheurer ME. Predictors of survival among older adults with ependymoma. Journal of Neuro-Oncology. 107: 183-9. PMID 21952907 DOI: 10.1007/S11060-011-0730-2 |
0.579 |
|
| 2012 |
Gilbert MR, Kuhn J, Lamborn KR, Lieberman F, Wen PY, Mehta M, Cloughesy T, Lassman AB, Deangelis LM, Chang S, Prados M. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. Journal of Neuro-Oncology. 106: 147-53. PMID 21739168 DOI: 10.1007/S11060-011-0650-1 |
0.424 |
|
| 2012 |
Theeler B, Gilbert M, Bondy M. Primary Brain and Central Nervous System Neoplasms in the Automated Central Tumor Registry: 2000-2010 (P07.108) Neurology. 78. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P07.108 |
0.375 |
|
| 2012 |
Hamza MA, Conrad CA, De Groot JF, Gilbert MR, Groves MD, Yung WKA, Puduvalli VK. Impact of duration of bevacizumab (Bev) treatment in the prognosis of adults with recurrent malignant gliomas. Journal of Clinical Oncology. 30: 2064-2064. DOI: 10.1200/Jco.2012.30.15_Suppl.2064 |
0.354 |
|
| 2012 |
Puduvalli VK, Groves MD, Gilbert MR, Hess KR, Kang S, Ictech S, Conrad CA, Loghin ME, De Groot JF, Levin VA, Yung WKA. Lenalidomide and irinotecan in adults with recurrent malignant gliomas: Phase I results of the phase I/II trial. Journal of Clinical Oncology. 30: 2036-2036. DOI: 10.1200/Jco.2012.30.15_Suppl.2036 |
0.319 |
|
| 2012 |
Anderson MD, Puduvalli VK, Hamza MA, Gilbert MR, Yung WKA. Differences in outcome due to bevacizumab (BEV) discontinuation versus BEV failure in adults with glioblastoma. Journal of Clinical Oncology. 30: 2030-2030. DOI: 10.1200/Jco.2012.30.15_Suppl.2030 |
0.334 |
|
| 2012 |
Wu J, Groves MD, Gilbert MR, Hess KR, Loch CS, Ictech S, De Groot JF, Conrad CA, Yung WKA, Puduvalli VK. Bevacizumab versus bevacizumab plus vorinostat in adults with recurrent malignant glioma: Results of a phase I part of a phase I/II trial. Journal of Clinical Oncology. 30: 2029-2029. DOI: 10.1200/Jco.2012.30.15_Suppl.2029 |
0.358 |
|
| 2012 |
Cahill DP, Beiko J, Suki D, Prabhu SS, Weinberg J, Lang FF, Gilbert MR, Rao G, McCutcheon IE, Aldape KD, Sawaya R. IDH1 status and survival benefit from surgical resection of enhancing and nonenhancing tumor in malignant astrocytomas. Journal of Clinical Oncology. 30: 2019-2019. DOI: 10.1200/Jco.2012.30.15_Suppl.2019 |
0.402 |
|
| 2012 |
Gilbert MR, Hess KR, Lagrone L, Groves MD, Levin VA, Groot JFD, Loghin ME, Puduvalli VK, Fisch M, Giglio P, Colman H, Conrad CA, Aldape KD, Yung WKA. Randomized phase II 8-arm factorial study of adjuvant dose-dense (dd) temozolomide (TMZ) with permutations of thalidomide (Thal), isotretinoin (CRA), and/or celecoxib (Cel) for newly diagnosed glioblastoma (GBM). Journal of Clinical Oncology. 30: 2003-2003. DOI: 10.1200/Jco.2012.30.15_Suppl.2003 |
0.353 |
|
| 2012 |
Chakravarti A, Wang M, Aldape KD, Sulman EP, Bredel M, Magliocco AM, Klimowicz AC, Hegi M, Stupp R, Gilbert MR, Curran WJ, Werner-Wasik M, Mahajan A, Schultz CJ, Mehta MP. A revised RTOG recursive partitioning analysis (RPA) model for glioblastoma based upon multiplatform biomarker profiles. Journal of Clinical Oncology. 30: 2001-2001. DOI: 10.1200/Jco.2012.30.15_Suppl.2001 |
0.365 |
|
| 2012 |
Habets EJ, Taphoorn MJ, Nederend S, Klein M, Delgadillo D, Hoang-Xuan K, Bottomley A, Allgeier A, Seute T, Gijtenbeek AM, De Gans J, Enting RH, Tijssen CC, Van den Bent MJ, Reijneveld JC, ... ... Gilbert MR, ... ... Gilbert MR, ... ... Gilbert M, ... ... Gilbert MR, ... ... Gilbert MR, ... ... Gilbert MR, et al. CLIN-SYMPTOM MANAGEMENT/QUALITY OF LIFE Neuro-Oncology. 14: vi153-vi159. DOI: 10.1093/Neuonc/Nos240 |
0.456 |
|
| 2011 |
Gilbert MR. Recurrent glioblastoma: a fresh look at current therapies and emerging novel approaches. Seminars in Oncology. 38: S21-33. PMID 22078645 DOI: 10.1053/J.Seminoncol.2011.09.008 |
0.36 |
|
| 2011 |
Gilbert MR. Improving patient outcomes in glioblastoma through integration of recent data: introduction. Seminars in Oncology. 38: S1. PMID 22078642 DOI: 10.1053/J.Seminoncol.2011.09.006 |
0.303 |
|
| 2011 |
Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, et al. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro-Oncology. 13: 1118-24. PMID 21813511 DOI: 10.1093/Neuonc/Nor110 |
0.389 |
|
| 2011 |
Shonka NA, Armstrong TS, Prabhu SS, Childress A, Choi S, Langford LA, Gilbert MR. Atypical teratoid/rhabdoid tumors in adults: a case report and treatment-focused review. Journal of Clinical Medicine Research. 3: 85-92. PMID 21811535 DOI: 10.4021/Jocmr535W |
0.565 |
|
| 2011 |
Wen PY, Schiff D, Cloughesy TF, Reardon DA, Batchelor TT, Chabner BA, Flaherty K, de Groot JF, Gilbert MR, Galanis E, Chang SM, Schwartz GK, Peereboom D, Mehta MP, Yung WK, et al. It is time to include patients with brain tumors in phase I trials in oncology. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3211-3. PMID 21768451 DOI: 10.1200/Jco.2011.36.6328 |
0.432 |
|
| 2011 |
de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, DeAngelis L, Camphausen K, Chen A, Yung WK, et al. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4872-81. PMID 21632852 DOI: 10.1158/1078-0432.Ccr-11-0271 |
0.323 |
|
| 2011 |
de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WK, Chen A, et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2689-95. PMID 21606416 DOI: 10.1200/Jco.2010.34.1636 |
0.448 |
|
| 2011 |
Armstrong TS, Vera-Bolanos E, Gilbert MR. Clinical course of adult patients with ependymoma: results of the Adult Ependymoma Outcomes Project. Cancer. 117: 5133-41. PMID 21538344 DOI: 10.1002/Cncr.26181 |
0.599 |
|
| 2011 |
Brem SS, Bierman PJ, Brem H, Butowski N, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Junck L, Linette GP, Loeffler JS, Maor MH, et al. Central nervous system cancers. Journal of the National Comprehensive Cancer Network : Jnccn. 9: 352-400. PMID 21464144 DOI: 10.6004/Jnccn.2011.0036 |
0.326 |
|
| 2011 |
Iwamoto FM, Lamborn KR, Kuhn JG, Wen PY, Yung WK, Gilbert MR, Chang SM, Lieberman FS, Prados MD, Fine HA. A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro-Oncology. 13: 509-16. PMID 21377994 DOI: 10.1093/Neuonc/Nor017 |
0.399 |
|
| 2011 |
Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, et al. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro-Oncology. 13: 353-61. PMID 21310734 DOI: 10.1093/Neuonc/Noq203 |
0.387 |
|
| 2011 |
Armstrong TS, Vera-Bolanos E, Gning I, Acquaye A, Gilbert MR, Cleeland C, Mendoza T. The impact of symptom interference using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) on prediction of recurrence in primary brain tumor patients. Cancer. 117: 3222-8. PMID 21264841 DOI: 10.1002/Cncr.25892 |
0.605 |
|
| 2011 |
Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling R, Shi W, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology. 13: 324-33. PMID 21149254 DOI: 10.1093/Neuonc/Noq157 |
0.395 |
|
| 2011 |
Melguizo I, Gilbert M, Tummala S. Guillain-Barré syndrome and glioblastoma. Journal of Neuro-Oncology. 104: 371-3. PMID 21104295 DOI: 10.1007/S11060-010-0471-7 |
0.386 |
|
| 2011 |
Armstrong TS, Gilbert MR. Patient profiling for treatment toxicity: potential use of clinical and genomic factors. Current Oncology Reports. 13: 37-41. PMID 21080116 DOI: 10.1007/S11912-010-0141-0 |
0.5 |
|
| 2011 |
Armstrong TS, Prabhu S, Aldape K, Hossan B, Kang S, Childress A, Tolentino L, Gilbert MR. A case of soft tissue metastasis from glioblastoma and review of the literature. Journal of Neuro-Oncology. 103: 167-72. PMID 20809248 DOI: 10.1007/S11060-010-0370-Y |
0.564 |
|
| 2011 |
Laack NN, O'Neill BP, Ballman KV, O'Fallon JR, Carrero XW, Kurtin PJ, Scheithauer BW, Brown PD, Habermann TM, Colgan JP, Gilbert MR, Hawkins RB, Morton RF, Windschitl HE, Fitch TR, et al. CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma. International Journal of Radiation Oncology, Biology, Physics. 81: 476-82. PMID 20800387 DOI: 10.1016/J.Ijrobp.2010.06.002 |
0.39 |
|
| 2011 |
Walbert T, Gilbert MR, Groves MD, Puduvalli VK, Yung WK, Conrad CA, Bobustuc GC, Colman H, Hsu SH, Bekele BN, Qiao W, Levin VA. Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma. Journal of Neuro-Oncology. 102: 273-80. PMID 20652724 DOI: 10.1200/Jco.2010.28.15_Suppl.2057 |
0.389 |
|
| 2011 |
Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Grewal J, Prabhu S, Loghin M, Gilbert MR, Jackson EF. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. International Journal of Radiation Oncology, Biology, Physics. 79: 1487-95. PMID 20399573 DOI: 10.1016/J.Ijrobp.2009.12.061 |
0.379 |
|
| 2011 |
Mammoser AG, Blas-Boria DE, Gilbert MR. Novel clinical trials in neuro-oncology Clinical Investigation. 1: 781-794. DOI: 10.4155/Cli.11.62 |
0.36 |
|
| 2011 |
Prithviraj GK, Sommers SR, Jump RL, Halmos B, Chambless LB, Parker SL, Hassam-Malani L, McGirt MJ, Thompson RC, Chambless LB, Parker SL, Hassam-Malani L, McGirt MJ, Thompson RC, Hunter K, ... ... Gilbert MR, ... ... Gilbert MR, ... ... Gilbert MR, ... ... Gilbert M, ... ... Gilbert MR, et al. MEDICAL AND NEURO-ONCOLOGY Neuro-Oncology. 13: iii41-iii68. DOI: 10.1093/Neuonc/Nor152 |
0.433 |
|
| 2011 |
Mehta M, Wang M, Aldape K, Sulman E, Stupp R, Jaeckle K, Blumenthal D, Erridge S, Curran W, Gilbert M. Clinical, Molecular, and Molecular-Clinical Profile (MCP) Exploratory Subset Analysis of RTOG 0525: a Phase III Trial Comparing Standard (std) Adjuvant Temozolomide (TMZ) with a Dose-dense (dd) Schedule for Glioblastoma (GBM) European Journal of Cancer. 47: 10. DOI: 10.1016/S0959-8049(11)70117-4 |
0.305 |
|
| 2010 |
Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh JJ, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 4722-9. PMID 20921459 DOI: 10.1200/Jco.2010.28.6963 |
0.326 |
|
| 2010 |
Rogers L, Gilbert MR, Vogelbaum MA. Intracranial meningiomas of atypical (WHO grade II) histology Journal of Neuro-Oncology. 99: 393-405. PMID 20740303 DOI: 10.1007/S11060-010-0343-1 |
0.319 |
|
| 2010 |
Gilbert MR, Gonzalez J, Hunter K, Hess K, Giglio P, Chang E, Puduvalli V, Groves MD, Colman H, Conrad C, Levin V, Woo S, Mahajan A, de Groot J, Yung WK. A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro-Oncology. 12: 1167-72. PMID 20729242 DOI: 10.1093/Neuonc/Noq100 |
0.349 |
|
| 2010 |
Yung WK, Vredenburgh JJ, Cloughesy TF, Nghiemphu P, Klencke B, Gilbert MR, Reardon DA, Prados MD. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro-Oncology. 12: 1061-70. PMID 20615922 DOI: 10.1093/Neuonc/Noq072 |
0.367 |
|
| 2010 |
Armstrong TS, Vera-Bolanos E, Bekele BN, Aldape K, Gilbert MR. Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience. Neuro-Oncology. 12: 862-70. PMID 20511182 DOI: 10.1093/Neuonc/Noq009 |
0.622 |
|
| 2010 |
Giglio P, Gilbert MR. Neurologic complications of cancer and its treatment Current Oncology Reports. 12: 50-59. PMID 20425608 DOI: 10.1007/S11912-009-0071-X |
0.315 |
|
| 2010 |
Gilbert MR, Ruda R, Soffietti R. Ependymomas in adults Current Neurology and Neuroscience Reports. 10: 240-247. PMID 20425040 DOI: 10.1007/S11910-010-0109-3 |
0.403 |
|
| 2010 |
Liu Y, Shete S, Etzel CJ, Scheurer M, Alexiou G, Armstrong G, Tsavachidis S, Liang FW, Gilbert M, Aldape K, Armstrong T, Houlston R, Hosking F, Robertson L, Xiao Y, et al. Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2467-74. PMID 20368557 DOI: 10.1200/Jco.2009.26.6213 |
0.511 |
|
| 2010 |
Armstrong TS, Gning I, Mendoza TR, Vera-Bolanos E, Gilbert MR, Rhines LD, Weinberg JS, Sanchez-Williams G, Levin V, Burton AW, Cleeland C. Reliability and validity of the M. D. Anderson Symptom Inventory-Spine Tumor Module. Journal of Neurosurgery. Spine. 12: 421-30. PMID 20367379 DOI: 10.3171/2009.10.Spine0943 |
0.564 |
|
| 2010 |
Armstrong TS, Cron SG, Bolanos EV, Gilbert MR, Kang DH. Risk factors for fatigue severity in primary brain tumor patients. Cancer. 116: 2707-15. PMID 20235192 DOI: 10.1002/Cncr.25018 |
0.569 |
|
| 2010 |
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1963-72. PMID 20231676 DOI: 10.1200/Jco.2009.26.3541 |
0.397 |
|
| 2010 |
Kilburn L, Okcu MF, Wang T, Cao Y, Renfro-Spelman A, Aldape KD, Gilbert MR, Bondy M. Glutathione S-transferase polymorphisms are associated with survival in anaplastic glioma patients. Cancer. 116: 2242-9. PMID 20187096 DOI: 10.1002/Cncr.25006 |
0.358 |
|
| 2010 |
Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN, Aldape KD. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro-Oncology. 12: 116-21. PMID 20150378 DOI: 10.1093/Neuonc/Nop020 |
0.361 |
|
| 2010 |
Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-Oncology. 12: 95-103. PMID 20150372 DOI: 10.1093/Neuonc/Nop015 |
0.374 |
|
| 2010 |
Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KD, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, et al. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro-Oncology. 12: 87-94. PMID 20150371 DOI: 10.1093/Neuonc/Nop017 |
0.306 |
|
| 2010 |
Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, Popoff S, Nutt CL, Louis DN, Cairncross JG, Gilbert MR, Phillips HS, Mehta MP, Chakravarti A, Pelloski CE, et al. A multigene predictor of outcome in glioblastoma. Neuro-Oncology. 12: 49-57. PMID 20150367 DOI: 10.1093/Neuonc/Nop007 |
0.332 |
|
| 2010 |
Armstrong TS, Choi S, Walker J, Gilbert MR. Seizure risk in brain tumor patients with conversion to generic levetiracetam. Journal of Neuro-Oncology. 98: 137-41. PMID 19936624 DOI: 10.1007/S11060-009-0066-3 |
0.516 |
|
| 2010 |
Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. Journal of Neuro-Oncology. 96: 211-7. PMID 19562255 DOI: 10.1007/S11060-009-9948-7 |
0.423 |
|
| 2009 |
Walbert T, Gilbert MR. The role of chemotherapy in the treatment of patients with brain metastases from solid tumors International Journal of Clinical Oncology. 14: 299-306. PMID 19705239 DOI: 10.1007/S10147-009-0916-1 |
0.397 |
|
| 2009 |
Groves MD, Puduvalli VK, Gilbert MR, Levin VA, Conrad CA, Liu VH, Hunter K, Meyers C, Hess KR, Alfred Yung WK. Two phase II trials of temozolomide with interferon-α2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme British Journal of Cancer. 101: 615-620. PMID 19672263 DOI: 10.1038/Sj.Bjc.6605189 |
0.388 |
|
| 2009 |
Armstrong TS, Cao Y, Scheurer ME, Vera-Bolaños E, Manning R, Okcu MF, Bondy M, Zhou R, Gilbert MR. Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. Neuro-Oncology. 11: 825-32. PMID 19179423 DOI: 10.1215/15228517-2008-120 |
0.509 |
|
| 2009 |
Tsien C, Moughan J, Michalski JM, Gilbert MR, Purdy J, Simpson J, Kresel JJ, Curran WJ, Diaz A, Mehta MP. Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03. International Journal of Radiation Oncology, Biology, Physics. 73: 699-708. PMID 18723297 DOI: 10.1016/J.Ijrobp.2008.05.034 |
0.362 |
|
| 2009 |
Armstrong TS, Gning I, Mendoza TR, Weinberg JS, Gilbert MR, Tortorice ML, Cleeland CS. Clinical utility of the MDASI-BT in patients with brain metastases. Journal of Pain and Symptom Management. 37: 331-40. PMID 18676120 DOI: 10.1016/J.Jpainsymman.2008.02.011 |
0.579 |
|
| 2009 |
Beadle BM, Mahajan A, Chang EL, Woo SY, McAleer MF, Sulman EP, Suki D, Gilbert MR, Pelloski CE. Prognostic Factors and Outcomes of Patients Treated with Re-irradiation for Recurrent Glioblastoma International Journal of Radiation Oncology Biology Physics. 75. DOI: 10.1016/J.Ijrobp.2009.07.566 |
0.328 |
|
| 2008 |
Armstrong TS, Cao Y, Vera E, Scheurer ME, Manning R, Okcu MF, Bondy M, Gilbert MR. Pharmacoepidemiology of myelotoxicity (TOX) with temozolomide (TMZ) in malignant glioma patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 9548. PMID 27948137 DOI: 10.1200/Jco.2008.26.15_Suppl.9548 |
0.556 |
|
| 2008 |
Shaw EG, Berkey B, Coons SW, Bullard D, Brachman D, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta M. Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. Journal of Neurosurgery. 109: 835-41. PMID 18976072 DOI: 10.3171/Jns/2008/109/11/0835 |
0.404 |
|
| 2008 |
Scheurer ME, Amirian E, Cao Y, Gilbert MR, Aldape KD, Kornguth DG, El-Zein R, Bondy ML. Polymorphisms in the interleukin-4 receptor gene are associated with better survival in patients with glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 6640-6. PMID 18927306 DOI: 10.1158/1078-0432.Ccr-07-4681 |
0.317 |
|
| 2008 |
de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V, Yung WK. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. Journal of Neuro-Oncology. 90: 89-97. PMID 18581057 DOI: 10.1007/S11060-008-9637-Y |
0.382 |
|
| 2008 |
Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Wen PY, Fine HA, Mehta MP, DeAngelis LM, Lieberman FS, Cloughesy TF, Robins HI, Abrey LE, Prados MD. Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro-Oncology. 10: 631-42. PMID 18559968 DOI: 10.1215/15228517-2008-021 |
0.366 |
|
| 2008 |
Armstrong TS, Gilbert MR. Use of complementary and alternative medical therapy by patients with primary brain tumors. Current Neurology and Neuroscience Reports. 8: 264-8. PMID 18541122 DOI: 10.1007/S11910-008-0040-Z |
0.592 |
|
| 2008 |
Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-Oncology. 10: 162-70. PMID 18356283 DOI: 10.1215/15228517-2007-062 |
0.428 |
|
| 2008 |
Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, Wefel JS, Gilbert MR, Ictech S, Hunter KU, Forman AD, Puduvalli VK, Colman H, Hess KR, Yung WK. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro-Oncology. 10: 208-15. PMID 18316473 DOI: 10.1215/15228517-2007-059 |
0.377 |
|
| 2008 |
Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert MR, Mahankali S, Jackson EF, Levin VA, Conrad CA, Hsu SH, Colman H, de Groot JF, Ritterhouse MG, Ictech SE, Yung WK. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro-Oncology. 10: 216-22. PMID 18314417 DOI: 10.1215/15228517-2007-060 |
0.389 |
|
| 2008 |
Heimberger AB, Sun W, Hussain SF, Dey M, Crutcher L, Aldape K, Gilbert M, Hassenbusch SJ, Sawaya R, Schmittling B, Archer GE, Mitchell DA, Bigner DD, Sampson JH. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro-Oncology. 10: 98-103. PMID 18079360 DOI: 10.1215/15228517-2007-046 |
0.322 |
|
| 2008 |
Robins HI, O'Neill A, Gilbert M, Olsen M, Sapiente R, Berkey B, Mehta M. Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial. Cancer Chemotherapy and Pharmacology. 62: 227-33. PMID 17882417 DOI: 10.1007/S00280-007-0596-3 |
0.398 |
|
| 2008 |
Tremont-Lukats I, Ratilal BO, Armstrong T, Gilbert MR. Antiepileptic drugs for preventing seizures in people with brain tumors Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.Cd004424.Pub2 |
0.531 |
|
| 2007 |
Gilbert MR, Armstrong TS. Management of patients with newly diagnosed malignant primary brain tumors with a focus on the evolving role of temozolomide. Therapeutics and Clinical Risk Management. 3: 1027-33. PMID 18516257 |
0.57 |
|
| 2007 |
De Groot JF, Gilbert MR. New molecular targets in malignant gliomas Current Opinion in Neurology. 20: 712-718. PMID 17992095 DOI: 10.1097/Wco.0B013E3282F15650 |
0.388 |
|
| 2007 |
Gilbert MR, Lang FF. Management of Patients with Low-Grade Gliomas Neurologic Clinics. 25: 1073-1088. PMID 17964026 DOI: 10.1016/J.Ncl.2007.07.007 |
0.357 |
|
| 2007 |
Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: Standard of care and future directions Journal of Clinical Oncology. 25: 4127-4136. PMID 17827463 DOI: 10.1200/Jco.2007.11.8554 |
0.391 |
|
| 2007 |
Ewend MG, Brem S, Gilbert M, Goodkin R, Penar PL, Varia M, Cush S, Carey LA. Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 3637-41. PMID 17575228 DOI: 10.1158/1078-0432.Ccr-06-2095 |
0.384 |
|
| 2007 |
Penas-Prado M, Gilbert MR. Molecularly targeted therapies for malignant gliomas: Advances and challenges Expert Review of Anticancer Therapy. 7: 641-661. PMID 17492929 DOI: 10.1586/14737140.7.5.641 |
0.352 |
|
| 2007 |
Armstrong TS, Gilbert MR. Net clinical benefit: functional endpoints in brain tumor clinical trials. Current Oncology Reports. 9: 60-5. PMID 17164049 DOI: 10.1007/Bf02951427 |
0.579 |
|
| 2007 |
Gilbert MR. Designing clinical trials for brain tumors: The next generation Current Oncology Reports. 9: 49-54. PMID 17164047 DOI: 10.1007/Bf02951425 |
0.417 |
|
| 2007 |
Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Hess KR, et al. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. Journal of Neuro-Oncology. 81: 271-7. PMID 17031561 DOI: 10.1007/S11060-006-9225-Y |
0.391 |
|
| 2007 |
Armstrong TS, Mendoza T, Gning I, Smith ML, Gilbert MR, Weinberg J, Cleeland C. The utility of the MDASI-BT in assessing symptoms in patients with brain metastases Journal of Clinical Oncology. 25: 2052-2052. DOI: 10.1200/Jco.2007.25.18_Suppl.2052 |
0.582 |
|
| 2007 |
Gilbert MR, Lang FF. Should patients with anaplastic oligodendroglial tumors receive adjuvant chemotherapy? Commentary Nature Clinical Practice Neurology. 3: 14-15. DOI: 10.1038/Ncpneuro0375 |
0.412 |
|
| 2006 |
Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4899-907. PMID 16914578 DOI: 10.1158/1078-0432.Ccr-06-0773 |
0.385 |
|
| 2006 |
Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer JJ, et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 3651-6. PMID 16877733 DOI: 10.1200/Jco.2006.06.2323 |
0.395 |
|
| 2006 |
Armstrong T, Cohen MZ, Hess KR, Manning R, Lee EL, Tamayo G, Baumgartner K, Min SJ, Yung A, Gilbert M. Complementary and alternative medicine use and quality of life in patients with primary brain tumors. Journal of Pain and Symptom Management. 32: 148-54. PMID 16877182 DOI: 10.1016/J.Jpainsymman.2006.02.015 |
0.583 |
|
| 2006 |
Gilbert MR, Lang FF. Anaplastic oligodendroglial tumors: A tale of two trials Journal of Clinical Oncology. 24: 2689-2690. PMID 16782906 DOI: 10.1200/Jco.2006.05.8594 |
0.453 |
|
| 2006 |
Groves MD, Puduvalli VK, Conrad CA, Gilbert MR, Yung WK, Jaeckle K, Liu V, Hess KR, Aldape KD, Levin VA. Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. Journal of Neuro-Oncology. 80: 83-90. PMID 16639492 DOI: 10.1007/S11060-006-9160-Y |
0.343 |
|
| 2006 |
Armstrong TS, Mendoza T, Gning I, Gring I, Coco C, Cohen MZ, Eriksen L, Hsu MA, Gilbert MR, Cleeland C. Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT). Journal of Neuro-Oncology. 80: 27-35. PMID 16598415 DOI: 10.1007/S11060-006-9135-Z |
0.582 |
|
| 2006 |
Wang L, Wei Q, Wang LE, Aldape KD, Cao Y, Okcu MF, Hess KR, El-Zein R, Gilbert MR, Woo SY, Prabhu SS, Fuller GN, Bondy ML. Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 1627-32. PMID 16575014 DOI: 10.1200/Jco.2005.04.0402 |
0.341 |
|
| 2006 |
Lang FF, Gilbert MR. Diffusely infiltrative low-grade gliomas in adults Journal of Clinical Oncology. 24: 1236-1245. PMID 16525178 DOI: 10.1200/Jco.2005.05.2399 |
0.344 |
|
| 2006 |
Gilbert MR. Advances in the treatment of primary brain tumors: Dawn of a new era? Current Oncology Reports. 8: 45-49. PMID 16464402 DOI: 10.1007/S11912-006-0008-6 |
0.43 |
|
| 2006 |
Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert M, Mahankali S, Hsu S, Colman H, Conrad C, Levin VA, Yung WKA. Phase II study of the combination of thalidomide and irinotecan in patients with recurrent anaplastic gliomas not on enzyme inducing anticonvulsants Journal of Clinical Oncology. 24: 1564-1564. DOI: 10.1200/Jco.2006.24.18_Suppl.1564 |
0.387 |
|
| 2006 |
Armstrong TS, Mendoza TR, Gning I, Coco C, Cohen MZ, Eriksen L, Hsu MA, Gilbert MR, Cleeland C. Erratum: Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT) (J Neurooncol 10.1007/s11060-006-9228-8) Journal of Neuro-Oncology. 80. DOI: 10.1007/S11060-006-9228-8 |
0.326 |
|
| 2005 |
Groves MD, Puduvalli V, Gilbert MR, Conrad CA, Hsu S, Colman H, Hess K, Levin VA, Yung WK. A phase II study of temozolomide plus pegylated interferon alfa-2b for recurrent anaplastic glioma and glioblastoma multiforme. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 1519. PMID 27947136 DOI: 10.1200/Jco.2005.23.16_Suppl.1519 |
0.343 |
|
| 2005 |
Manon R, O'Neill A, Knisely J, Werner-Wasik M, Lazarus HM, Wagner H, Gilbert MR, Mehta M. Phase II Trial of Radiosurgery for One to Three Newly Diagnosed Brain Metastases From Renal Cell Carcinoma, Melanoma, and Sarcoma: An Eastern Cooperative Oncology Group Study (E 6397) Journal of Clinical Oncology. 23: 8870-8876. PMID 16314647 DOI: 10.1200/Jco.2005.01.8747 |
0.383 |
|
| 2005 |
Gonzalez J, Gilbert MR. Treatment of astrocytomas Current Opinion in Neurology. 18: 632-638. PMID 16280673 DOI: 10.1097/01.Wco.0000191510.14627.D2 |
0.443 |
|
| 2005 |
Lassman AB, Rossi MR, Raizer JJ, Razier JR, Abrey LE, Lieberman FS, Grefe CN, Lamborn K, Pao W, Shih AH, Kuhn JG, Wilson R, Nowak NJ, Cowell JK, DeAngelis LM, ... ... Gilbert MR, et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 7841-50. PMID 16278407 DOI: 10.1158/1078-0432.Ccr-05-0421 |
0.377 |
|
| 2005 |
Pelloski CE, Mahajan A, Maor M, Chang EL, Woo S, Gilbert M, Colman H, Yang H, Ledoux A, Blair H, Passe S, Jenkins RB, Aldape KD. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 3326-34. PMID 15867231 DOI: 10.1158/1078-0432.Ccr-04-1765 |
0.37 |
|
| 2005 |
Phuphanich S, Baker SD, Grossman SA, Carson KA, Gilbert MR, Fisher JD, Carducci MA. Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study Neuro-Oncology. 7: 177-182. PMID 15831235 DOI: 10.1215/S1152851704000183 |
0.347 |
|
| 2005 |
Armstrong T, Almadrones L, Gilbert MR. Chemotherapy-induced peripheral neuropathy Oncology Nursing Forum. 32: 305-311. PMID 15759068 DOI: 10.1188/05.Onf.305-311 |
0.508 |
|
| 2005 |
Chang SM, Seiferheld W, Curran W, Share R, Atkins J, Choucair A, Kresl J, Thoron L, Cairncross G, Gilbert M, Bahary JP, Dolinskas C, Louis DN, Bushunow P, Buckner JC, et al. Erratum: Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): Implications for studies testing initial treatment of brain tumors (International Journal of Radiation Oncology Biology Physics (2004) 59 (1122-1126)) International Journal of Radiation Oncology Biology Physics. 61. DOI: 10.1016/J.Ijrobp.2004.10.034 |
0.349 |
|
| 2004 |
Armstrong TS, Cohen MZ, Weinberg J, Gilbert MR. Imaging techniques in neuro-oncology. Seminars in Oncology Nursing. 20: 231-9. PMID 15612599 DOI: 10.1016/J.Soncn.2004.07.003 |
0.546 |
|
| 2004 |
Puduvalli VK, Yung WK, Hess KR, Kuhn JG, Groves MD, Levin VA, Zwiebel J, Chang SM, Cloughesy TF, Junck L, Wen P, Lieberman F, Conrad CA, Gilbert MR, Meyers CA, et al. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 4282-9. PMID 15514370 DOI: 10.1200/Jco.2004.09.096 |
0.393 |
|
| 2004 |
See SJ, Gilbert MR. Anaplastic astrocytoma: Diagnosis, prognosis, and management Seminars in Oncology. 31: 618-634. PMID 15497115 DOI: 10.1053/J.Seminoncol.2004.07.004 |
0.422 |
|
| 2004 |
Armstrong TS, Gilbert MR. The treatment of neoplastic meningitis. Expert Opinion On Pharmacotherapy. 5: 1929-35. PMID 15330730 DOI: 10.1517/14656566.5.9.1929 |
0.541 |
|
| 2004 |
Chang SM, Seiferheld W, Curran W, Share R, Atkins J, Choucair A, Kresl J, Thoron L, Cairncross G, Gilbert M, Bahary JP, Dolinskas C, Louis DN, Bushunow P, Buckner J, et al. Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors. International Journal of Radiation Oncology, Biology, Physics. 59: 1122-6. PMID 15234047 DOI: 10.1016/J.Ijrobp.2004.01.002 |
0.39 |
|
| 2004 |
Batchelor TT, Gilbert MR, Supko JG, Carson KA, Nabors LB, Grossman SA, Lesser GJ, Mikkelsen T, Phuphanich S. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro-Oncology. 6: 21-7. PMID 14769136 DOI: 10.1215/S1152851703000218 |
0.396 |
|
| 2004 |
Laterra JJ, Grossman SA, Carson KA, Lesser GJ, Hochberg FH, Gilbert MR. Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study. Neuro-Oncology. 6: 15-20. PMID 14769135 DOI: 10.1215/S1152851703000127 |
0.414 |
|
| 2004 |
Armstrong T, Gilbert MR. Central nervous system toxicity from cancer treatment Current Oncology Reports. 6: 11-19. PMID 14664755 DOI: 10.1007/S11912-996-0004-X |
0.547 |
|
| 2003 |
Chang SM, Kuhn JG, Ian Robins H, Clifford Schold S, Spence AM, Berger MS, Mehta MP, Pollack I, Gilbert M, Prados MD. A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors consortium report. Investigational New Drugs. 21: 429-33. PMID 14586210 DOI: 10.1023/A:1026299118067 |
0.384 |
|
| 2003 |
Giglio P, Gilbert MR. Cerebral radiation necrosis Neurologist. 9: 180-188. PMID 12864928 DOI: 10.1097/01.Nrl.0000080951.78533.C4 |
0.315 |
|
| 2003 |
Tremont-Lukats IW, Gilbert MR. Advances in molecular therapies in patients with brain tumors Cancer Control. 10: 125-137. PMID 12712007 DOI: 10.1177/107327480301000204 |
0.418 |
|
| 2003 |
Grossman SA, O'Neill A, Grunnet M, Mehta M, Pearlman JL, Wagner H, Gilbert M, Newton HB, Hellman R. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394 Journal of Clinical Oncology. 21: 1485-1491. PMID 12697871 DOI: 10.1200/Jco.2003.10.035 |
0.381 |
|
| 2003 |
Armstrong TS, Kanusky JT, Gilbert MR. Seize the moment to learn about epilepsy in people with cancer. Clinical Journal of Oncology Nursing. 7: 163-9. PMID 12696212 DOI: 10.1188/03.Cjon.163-169 |
0.489 |
|
| 2003 |
Gilbert MR. Neoplastic meningitis: A unique disease process or a 'test tube' for evaluating cancer treatments? Current Oncology Reports. 5: 11-14. PMID 12493145 DOI: 10.1007/S11912-003-0081-Z |
0.342 |
|
| 2002 |
Armstrong TS, Gilbert MR. Glial tumors--new approaches in chemotherapy. The Journal of Neuroscience Nursing : Journal of the American Association of Neuroscience Nurses. 34: 326-30. PMID 12506816 DOI: 10.1097/01376517-200212000-00007 |
0.58 |
|
| 2002 |
Gilbert MR, Friedman HS, Kuttesch JF, Prados MD, Olson JJ, Reaman GH, Zaknoen SL. A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro-Oncology. 4: 261-7. PMID 12356356 DOI: 10.1093/Neuonc/4.4.261 |
0.391 |
|
| 2001 |
Gilbert MR. Brain metastases: still an 'orphan' disease? Current Oncology Reports. 3: 463-466. PMID 11595113 DOI: 10.1007/S11912-001-0066-8 |
0.372 |
|
| 2000 |
Gilbert MR. Brain tumor clinical trials: pitfalls and promise for the future Current Oncology Reports. 2: 473-475. PMID 11122880 DOI: 10.1007/S11912-000-0095-8 |
0.459 |
|
| 2000 |
Takeshima H, Sawamura Y, Gilbert MR, Van Meir EG. Application of advances in molecular biology to the treatment of brain tumors Current Oncology Reports. 2: 425-433. PMID 11122874 DOI: 10.1007/S11912-000-0062-4 |
0.375 |
|
| 1999 |
Grunnet ML, OʼNeill A, Gilbert M, Hellman R. CORRELATION OF TUMOR p53 AND PCNA WITH RESPONSE AND SURVIVAL OF GLIOBLSTOMA PATIENTS TREATED WITH AN ECOG PROTOCOL OF PRE-IRRADIATION CHEMOTHERAPY Journal of Neuropathology and Experimental Neurology. 58: 513. DOI: 10.1097/00005072-199905000-00028 |
0.388 |
|
| 1998 |
Chang SM, Kuhn JG, Rizzo J, Robins HI, Schold SC, Spence AM, Berger MS, Mehta MP, Bozik ME, Pollack I, Gilbert M, Fulton D, Rankin C, Malec M, Prados MD. Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 2188-94. PMID 9626220 DOI: 10.1200/Jco.1998.16.6.2188 |
0.374 |
|
| 1989 |
Grossman SA, Sheidler VR, Gilbert MR. Decreased phenytoin levels in patients receiving chemotherapy The American Journal of Medicine. 87: 505-510. PMID 2683764 DOI: 10.1016/S0002-9343(89)80605-9 |
0.352 |
|
| 1986 |
Gilbert MR, Grossman SA. Incidence and nature of neurologic problems in patients with solid tumors The American Journal of Medicine. 81: 951-954. PMID 3799654 DOI: 10.1016/0002-9343(86)90385-2 |
0.351 |
|
| 1985 |
Weissman DE, Gilbert M, Wang H, Grossman SA. The use of computed tomography of the spine to identify patients at high risk for epidural metastases. Journal of Clinical Oncology. 3: 1541-1544. PMID 4056845 DOI: 10.1200/Jco.1985.3.11.1541 |
0.346 |
|
| Show low-probability matches. |